|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
MX349137B
(es)
|
2005-06-08 |
2017-07-13 |
Dana-Farber Cancer Inst |
Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
|
|
CN104356236B
(zh)
*
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
JP2010504356A
(ja)
*
|
2006-09-20 |
2010-02-12 |
ザ ジョンズ ホプキンス ユニバーシティー |
抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
|
|
EP2102241A2
(en)
*
|
2006-12-15 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
AU2013200388B2
(en)
*
|
2006-12-27 |
2014-10-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for the treatment of infections and tumors
|
|
DK2132229T3
(en)
*
|
2007-03-01 |
2016-06-20 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
|
|
WO2008156712A1
(en)
|
2007-06-18 |
2008-12-24 |
N. V. Organon |
Antibodies to human programmed death receptor pd-1
|
|
US20110014117A1
(en)
*
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
WO2009012394A1
(en)
|
2007-07-17 |
2009-01-22 |
Medarex, Inc. |
Monoclonal antibodies against glypican-3
|
|
US8062852B2
(en)
*
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
|
CA2708854C
(en)
*
|
2007-12-14 |
2017-11-28 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
|
EP3153526B1
(en)
|
2008-01-31 |
2020-09-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
ES2758126T3
(es)
|
2008-04-09 |
2020-05-04 |
Genentech Inc |
Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP2350129B1
(en)
|
2008-08-25 |
2015-06-10 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
EP2328919A2
(en)
*
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
AU2013204861B2
(en)
*
|
2008-09-26 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
JP5520961B2
(ja)
|
2008-11-28 |
2014-06-11 |
エモリー ユニバーシティ |
感染症および腫瘍を処置するための方法
|
|
TW202442680A
(zh)
*
|
2008-12-09 |
2024-11-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
WO2010089411A2
(en)
*
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
PT2415470T
(pt)
|
2009-03-30 |
2016-08-31 |
Eisai R&D Man Co Ltd |
Composição de lipossomas
|
|
AU2010242598C1
(en)
|
2009-04-27 |
2015-02-05 |
Kyowa Kirin Co., Ltd. |
Anti-IL-3Ralpha antibody for use in treatment of blood tumor
|
|
BRPI1012675A2
(pt)
|
2009-06-26 |
2016-04-05 |
Soricimed Biopharma Inc |
compostos e métodos para a detecção de cânceres expressando trpv-6 e liberação de fármacos
|
|
AU2010303149B2
(en)
|
2009-09-30 |
2016-08-04 |
Board Of Regents, The University Of Texas System |
Combination immunotherapy for the treatment of cancer
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
|
US20110280877A1
(en)
*
|
2010-05-11 |
2011-11-17 |
Koji Tamada |
Inhibition of B7-H1/CD80 interaction and uses thereof
|
|
MX342405B
(es)
|
2010-06-03 |
2016-09-28 |
Pharmacyclics Inc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US9226958B2
(en)
|
2010-10-01 |
2016-01-05 |
University Of Georgia Research Foundation, Inc. |
Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
|
|
AU2012229218B2
(en)
|
2011-03-11 |
2017-03-02 |
Advaxis, Inc. |
Listeria-based adjuvants
|
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
EP2712655B1
(en)
|
2011-04-28 |
2019-12-18 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
|
LT3473267T
(lt)
|
2011-05-24 |
2021-11-25 |
BioNTech SE |
Individualizuotos vakcinos nuo vėžio
|
|
WO2012168944A1
(en)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
WO2012178137A1
(en)
|
2011-06-24 |
2012-12-27 |
Gillies Stephen D |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
|
TWI835048B
(zh)
*
|
2011-08-01 |
2024-03-11 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
|
JP6038921B2
(ja)
|
2011-08-30 |
2016-12-07 |
アステックス ファーマシューティカルズ インコーポレイテッド |
デシタビン誘導体製剤
|
|
MX349096B
(es)
*
|
2011-11-28 |
2017-07-11 |
Merck Patent Gmbh |
Anticuerpos anti-pd-l1 y sus usos.
|
|
WO2013112942A1
(en)
*
|
2012-01-25 |
2013-08-01 |
Dna Trix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
HK1205944A1
(en)
|
2012-03-12 |
2015-12-31 |
阿德瓦希斯公司 |
Suppressor cell function inhibition following listeria vaccine treatment
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
EP2836234B1
(en)
|
2012-04-12 |
2019-06-12 |
Yale University |
Vehicles for controlled delivery of different pharmaceutical agents
|
|
EA037351B8
(ru)
*
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
|
|
US9175082B2
(en)
*
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
EP3495367B1
(en)
|
2012-06-13 |
2020-09-30 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
BR112015001690A2
(pt)
|
2012-07-24 |
2017-11-07 |
Pharmacyclics Inc |
mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
|
|
US9790184B2
(en)
|
2012-07-27 |
2017-10-17 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
|
EP2890715B1
(en)
|
2012-08-03 |
2020-12-16 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
|
|
KR101594032B1
(ko)
*
|
2012-08-23 |
2016-02-15 |
강원대학교산학협력단 |
염증 또는 피부노화의 예방 또는 치료용 약학 조성물 및 염증 또는 피부노화 개선용 화장료 조성물
|
|
CN104704002B
(zh)
|
2012-08-30 |
2022-05-10 |
安姆根有限公司 |
使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
|
|
EP2904011B1
(en)
|
2012-10-02 |
2017-08-23 |
Bristol-Myers Squibb Company |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
CN104994873B
(zh)
*
|
2012-10-04 |
2017-12-22 |
达纳－法伯癌症研究所公司 |
人单克隆抗‑pd‑l1抗体和使用方法
|
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
US11230589B2
(en)
|
2012-11-05 |
2022-01-25 |
Foundation Medicine, Inc. |
Fusion molecules and uses thereof
|
|
US10155031B2
(en)
|
2012-11-28 |
2018-12-18 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
|
EP2954327A1
(en)
|
2013-02-07 |
2015-12-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
|
EP2958942B1
(en)
|
2013-02-20 |
2020-06-03 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
SG10201710472PA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
BR122021025267B1
(pt)
|
2013-02-22 |
2023-12-05 |
Curevac Ag |
Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
|
|
CN105025884B
(zh)
|
2013-03-01 |
2019-08-20 |
阿斯泰克斯制药公司 |
药物组合
|
|
CA2901269C
(en)
|
2013-03-06 |
2022-01-18 |
Astrazeneca Ab |
Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
|
|
RS56531B1
(sr)
|
2013-03-14 |
2018-02-28 |
Bristol Myers Squibb Co |
Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene
|
|
MY176706A
(en)
*
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP2981821B2
(en)
|
2013-04-02 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
WO2014168941A1
(en)
|
2013-04-09 |
2014-10-16 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
KR20150139955A
(ko)
|
2013-04-09 |
2015-12-14 |
보스톤 바이오메디칼, 인크. |
암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
|
|
DK2986610T5
(en)
|
2013-04-19 |
2018-12-10 |
Incyte Holdings Corp |
BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
JP6563906B2
(ja)
*
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｐｄ−１に結合する抗原結合蛋白質
|
|
BR112015028326A8
(pt)
|
2013-06-03 |
2018-01-23 |
Novartis Ag |
combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
|
|
MX384142B
(es)
|
2013-07-16 |
2025-03-14 |
Genentech Inc |
Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
|
|
MX374291B
(es)
|
2013-08-08 |
2025-03-06 |
Cytune Pharma |
Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
|
|
HUE046964T2
(hu)
|
2013-08-08 |
2020-04-28 |
Cytune Pharma |
Kombinált gyógyászati készítmény
|
|
EP3035964B1
(en)
|
2013-08-20 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
Treating cancer with a combination of a pd-1 antagonist and dinaciclib
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
US10081681B2
(en)
|
2013-09-20 |
2018-09-25 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US10202454B2
(en)
*
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
EP3060251A4
(en)
*
|
2013-10-25 |
2017-12-06 |
Pharmacyclics LLC |
Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
|
|
KR102460800B1
(ko)
|
2013-11-01 |
2022-10-31 |
예일 유니버시티 |
면역요법용 모듈러 입자
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
US20150140036A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Institutes For Biomedical Research, Inc. |
Low, immune enhancing, dose mtor inhibitors and uses thereof
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015081158A1
(en)
*
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
WO2015088930A1
(en)
|
2013-12-10 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
CN106029696B
(zh)
*
|
2013-12-17 |
2020-07-28 |
基因泰克公司 |
抗cd3抗体及使用方法
|
|
US9045545B1
(en)
*
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
|
US20160304969A1
(en)
|
2013-12-17 |
2016-10-20 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
|
SG10201808519VA
(en)
|
2013-12-17 |
2018-10-30 |
Genentech Inc |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
|
US9067998B1
(en)
*
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
|
CA2934073A1
(en)
|
2013-12-20 |
2015-06-25 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
EA032469B1
(ru)
|
2013-12-24 |
2019-05-31 |
Бристол-Маерс Сквибб Компани |
Новые трициклические соединения в качестве противораковых средств
|
|
EP4070818A3
(en)
*
|
2014-01-06 |
2023-01-11 |
The Trustees of the University of Pennsylvania |
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
|
|
SG11201605296SA
(en)
|
2014-01-10 |
2016-07-28 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for treating her2 positive tumors
|
|
WO2015109124A2
(en)
*
|
2014-01-15 |
2015-07-23 |
Kadmon Corporation, Llc |
Immunomodulatory agents
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
ES2877356T3
(es)
|
2014-01-27 |
2021-11-16 |
Molecular Templates Inc |
Epítopo de MHC de clase I que suministra polipéptidos
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
PT3102605T
(pt)
|
2014-02-04 |
2019-02-12 |
Pfizer |
Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
|
|
EP3102604B1
(en)
|
2014-02-04 |
2020-01-15 |
Pfizer Inc |
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
|
|
SG11201606428UA
(en)
|
2014-02-04 |
2016-09-29 |
Incyte Corp |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
DK3105246T3
(da)
|
2014-02-10 |
2021-06-14 |
Merck Patent Gmbh |
Målrettet TGF-beta-inhibering
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20170088626A1
(en)
|
2014-03-05 |
2017-03-30 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
KR102248804B1
(ko)
|
2014-03-12 |
2021-05-11 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
JP2017509336A
(ja)
|
2014-03-20 |
2017-04-06 |
ファーマサイクリックス エルエルシー |
ホスホリパーゼｃガンマ２及び耐性に関連した変異
|
|
UA121383C2
(uk)
|
2014-03-24 |
2020-05-25 |
Новартіс Аг |
Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій
|
|
WO2015148683A1
(en)
*
|
2014-03-26 |
2015-10-01 |
Tocagen Inc. |
A retroviral vector having immune-stimulating activity
|
|
WO2015153513A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
US9987258B2
(en)
|
2014-04-06 |
2018-06-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase as a modulator of PDL1 expression and activity
|
|
ES2876263T3
(es)
|
2014-04-07 |
2021-11-12 |
Novartis Ag |
Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
|
|
US20170044496A1
(en)
|
2014-04-10 |
2017-02-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
PL3142751T3
(pl)
*
|
2014-05-13 |
2019-12-31 |
Medimmune Limited |
Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
|
|
CA2949121A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
WO2015179615A1
(en)
|
2014-05-23 |
2015-11-26 |
Eisai R&D Management Co., Ltd |
Combination therapies for the treatment of cancer
|
|
WO2015184061A2
(en)
*
|
2014-05-28 |
2015-12-03 |
Dana-Farber Cancer Institute, Inc. |
Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
|
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
|
EP3151820A4
(en)
|
2014-06-06 |
2017-11-22 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
AU2015274647C1
(en)
|
2014-06-11 |
2020-01-30 |
Molecular Templates, Inc. |
Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR102130600B1
(ko)
*
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
DK3166976T3
(da)
|
2014-07-09 |
2022-04-11 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1-kombinationer til behandling af tumorer
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
WO2016011160A1
(en)
|
2014-07-15 |
2016-01-21 |
Genentech, Inc. |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
EP3193921A4
(en)
|
2014-07-18 |
2018-04-25 |
Advaxis, Inc. |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
BR122020025583B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
US10435470B2
(en)
*
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
|
WO2016020836A1
(en)
|
2014-08-06 |
2016-02-11 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
|
US10392444B2
(en)
*
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
|
PL3177640T3
(pl)
*
|
2014-08-08 |
2020-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
|
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
|
EP3185866A1
(en)
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
DK3186281T3
(da)
|
2014-08-28 |
2019-06-11 |
Halozyme Inc |
Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
|
|
WO2016030455A1
(en)
*
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
|
JP6681905B2
(ja)
|
2014-09-13 |
2020-04-15 |
ノバルティス アーゲー |
Ａｌｋ阻害剤の併用療法
|
|
DK3193931T3
(da)
|
2014-09-16 |
2020-10-19 |
Innate Pharma |
Neutralisering af hæmmende veje i lymfocytter
|
|
KR20210149228A
(ko)
|
2014-09-17 |
2021-12-08 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
EP3689910A3
(en)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
CN107074952B
(zh)
*
|
2014-09-30 |
2021-04-09 |
英特维特国际股份有限公司 |
结合犬pd-l1的pd-l1抗体
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US10774388B2
(en)
|
2014-10-08 |
2020-09-15 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
EP3204417B1
(en)
|
2014-10-10 |
2020-07-22 |
Innate Pharma |
Cd73 blockade
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
EA201790834A1
(ru)
*
|
2014-10-14 |
2018-01-31 |
Новартис Аг |
Молекулы антител к pd-l1 и их применение
|
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
|
PL3209778T3
(pl)
|
2014-10-24 |
2019-08-30 |
Astrazeneca Ab |
Kombinacja
|
|
HUE054526T2
(hu)
|
2014-10-29 |
2021-09-28 |
Bicyclerd Ltd |
MT1-MMP-ra specifikus biciklusos peptid ligandumok
|
|
IL251464B2
(en)
|
2014-10-29 |
2023-03-01 |
Five Prime Therapeutics Inc |
Combination therapy for cancer
|
|
EP4653013A2
(en)
|
2014-10-31 |
2025-11-26 |
The Trustees of the University of Pennsylvania |
Methods and compositions for modified t cells
|
|
PT3212233T
(pt)
*
|
2014-10-31 |
2020-07-16 |
Oncomed Pharm Inc |
Terapia combinada para o tratamento de doenças
|
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
EP3215182B1
(en)
|
2014-11-05 |
2023-01-04 |
The Regents of The University of California |
Combination immunotherapy
|
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
|
MX2017005462A
(es)
|
2014-11-05 |
2017-07-28 |
Flexus Biosciences Inc |
Agentes inmunorreguladores.
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
KR20170084202A
(ko)
|
2014-11-14 |
2017-07-19 |
노파르티스 아게 |
항체 약물 접합체
|
|
KR20170096112A
(ko)
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
|
HRP20201928T1
(hr)
|
2014-11-20 |
2021-02-05 |
F. Hoffmann - La Roche Ag |
Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
|
|
WO2016081854A1
(en)
|
2014-11-20 |
2016-05-26 |
Promega Corporation |
Systems and methods for assessing modulators of immune checkpoints
|
|
ES2807182T3
(es)
|
2014-11-21 |
2021-02-22 |
Bristol Myers Squibb Co |
Anticuerpos frente a CD73 y sus usos
|
|
WO2016081746A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
CA2968961A1
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
EA037590B1
(ru)
|
2014-11-25 |
2021-04-19 |
Бристол-Майерс Сквибб Компани |
Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
|
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
KR20170088984A
(ko)
|
2014-12-04 |
2017-08-02 |
브리스톨-마이어스 스큅 컴퍼니 |
암 (골수종)을 치료하기 위한 항-cs1 항체와 항-pd1 항체의 조합
|
|
WO2016090300A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
|
EP3226690B1
(en)
|
2014-12-05 |
2020-05-20 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
US10442819B2
(en)
|
2014-12-05 |
2019-10-15 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
EP3226689B1
(en)
|
2014-12-05 |
2020-01-15 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
CA2968406A1
(en)
|
2014-12-09 |
2016-06-16 |
Mark D. Ayers |
System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
|
|
HUE067123T2
(hu)
|
2014-12-09 |
2024-10-28 |
Regeneron Pharma |
Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
|
|
EA032138B1
(ru)
|
2014-12-16 |
2019-04-30 |
Новартис Аг |
СОЕДИНЕНИЯ ИЗОКСАЗОЛГИДРОКСАМИНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LpxC
|
|
KR102549746B1
(ko)
|
2014-12-18 |
2023-07-03 |
암젠 인크 |
안정한 동결된 단순 포진 바이러스 제제
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
ES3049406T3
(en)
|
2014-12-19 |
2025-12-16 |
Broad Inst Inc |
Methods for profiling the t-cell-receptor repertoire
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
ＴＧＦβＲ拮抗劑
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
RS61470B1
(sr)
|
2014-12-31 |
2021-03-31 |
Checkmate Pharmaceuticals Inc |
Kombinovana antitumorska imunoterapija
|
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
US10828353B2
(en)
*
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
MX2017010072A
(es)
*
|
2015-02-05 |
2017-11-09 |
Molecular Templates Inc |
Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
CR20170390A
(es)
|
2015-02-20 |
2017-10-23 |
Incyte Holdings Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
BR112017018234A2
(pt)
*
|
2015-02-26 |
2018-04-17 |
Merck Patent Gmbh |
inibidores de pd-1 / pd-l1 para o tratamento de câncer
|
|
RU2742312C1
(ru)
*
|
2015-02-26 |
2021-02-04 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
|
AU2016226468B2
(en)
|
2015-03-02 |
2020-10-22 |
Bristol-Myers Squibb Company |
TGF-beta inhibitors
|
|
BR112017018872A2
(pt)
|
2015-03-04 |
2018-05-29 |
Eisai R&D Man Co Ltd |
combinação de um antagonista pd-1 e eribulina para tratamento de câncer
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
JP6769982B2
(ja)
|
2015-03-06 |
2020-10-14 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
Ｒａｓ変異と関連するがんの治療方法
|
|
EP3265091A4
(en)
|
2015-03-06 |
2018-08-01 |
Beyondspring Pharmaceuticals Inc. |
Method of treating a brain tumor
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
IL292449B2
(en)
*
|
2015-03-13 |
2024-02-01 |
Cytomx Therapeutics Inc |
Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
JP6815329B2
(ja)
|
2015-03-23 |
2021-01-20 |
バイエル ファーマ アクチエンゲゼルシャフト |
抗ｃｅａｃａｍ６抗体およびその使用
|
|
WO2016161410A2
(en)
|
2015-04-03 |
2016-10-06 |
Xoma Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
MX2017012729A
(es)
|
2015-04-03 |
2017-11-15 |
Bristol Myers Squibb Co |
Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
|
JP6999421B2
(ja)
|
2015-04-07 |
2022-02-04 |
アレクトル エルエルシー |
抗ソルチリン抗体及びその使用方法
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3283882B2
(en)
|
2015-04-17 |
2024-10-16 |
Merck Sharp & Dohme LLC |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
DK3283107T3
(da)
|
2015-04-17 |
2020-08-31 |
Bristol Myers Squibb Co |
Sammensætninger omfattende en kombination af ipilimumab og nivolumab
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
AU2016262074A1
(en)
|
2015-05-12 |
2017-11-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
PT3298021T
(pt)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
HRP20201031T1
(hr)
|
2015-05-29 |
2020-10-16 |
Agenus Inc. |
Anti-ctla-4 protutijela i postupci njihove upotrebe
|
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
HK1255200A1
(zh)
*
|
2015-05-29 |
2019-08-09 |
F. Hoffmann-La Roche Ag |
癌症中pd-l1启动子甲基化
|
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
|
MA44699A
(fr)
|
2015-05-29 |
2021-05-05 |
Merck Sharp & Dohme |
Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
CN115554399A
(zh)
|
2015-05-31 |
2023-01-03 |
源生公司 |
用于免疫疗法的组合组合物
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
US20180179282A1
(en)
|
2015-06-12 |
2018-06-28 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
RU2766890C2
(ru)
|
2015-06-16 |
2022-03-16 |
Мерк Патент Гмбх |
Комбинированные способы лечения антагонистами pd-l1
|
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
CA2990015A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
MX2018000016A
(es)
|
2015-07-02 |
2019-01-31 |
Otsuka Pharma Co Ltd |
Composiciones farmaceuticas liofilizadas.
|
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
CN108026075B
(zh)
|
2015-07-13 |
2021-06-29 |
大连万春布林医药有限公司 |
普那布林组合物
|
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
BR112018000917A2
(pt)
|
2015-07-16 |
2018-09-11 |
Bioxcel Therapeutics Inc |
abordagem inovadora para o tratamento de câncer através da imunomodulação
|
|
SG10201912978PA
(en)
|
2015-07-21 |
2020-02-27 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
RU2018105846A
(ru)
|
2015-07-29 |
2019-08-28 |
Новартис Аг |
Комбинация антагониста pd-1 с ингибитором egfr
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
ES2898958T3
(es)
|
2015-07-30 |
2022-03-09 |
Macrogenics Inc |
Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
|
|
CN106397592A
(zh)
*
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
WO2017025498A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
US11008391B2
(en)
|
2015-08-11 |
2021-05-18 |
WuXi Biologics Ireland Limited |
Anti-PD-1 antibodies
|
|
JP6596146B2
(ja)
|
2015-08-13 |
2019-10-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド化合物
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
KR20180042370A
(ko)
|
2015-08-25 |
2018-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
|
US11385231B2
(en)
|
2015-08-27 |
2022-07-12 |
Inserm (Institut National De La Sante Et De La Recherche Scientifique) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
NZ740351A
(en)
|
2015-09-03 |
2022-10-28 |
Ono Pharmaceutical Co |
Immunity enhancing agent for cancer by allergin-1 antagonist
|
|
EP3344275B8
(en)
|
2015-09-03 |
2023-04-12 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
EP3356551B1
(en)
|
2015-09-29 |
2020-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of b-lymphomas
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
US20180282415A1
(en)
|
2015-09-30 |
2018-10-04 |
Merck Patent Gmbh |
Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
|
|
JP2018530550A
(ja)
|
2015-10-01 |
2018-10-18 |
ギリアド サイエンシズ， インコーポレイテッド |
癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
|
|
UA123826C2
(uk)
|
2015-10-02 |
2021-06-09 |
Ф. Хоффманн-Ля Рош Аг |
Антитіла до pd1 та способи їх застосування
|
|
IL257110B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Bispecific antibodies specific against pd1 and tim3
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
EP3359192A4
(en)
|
2015-10-08 |
2019-05-01 |
MacroGenics, Inc. |
COMBINATION THERAPY FOR CANCER TREATMENT
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
ES2994611T3
(en)
|
2015-10-19 |
2025-01-27 |
Cg Oncology Inc |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CA3004804A1
(en)
|
2015-11-17 |
2017-05-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
|
|
US11072657B2
(en)
|
2015-11-18 |
2021-07-27 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
|
|
SG10201911035QA
(en)
|
2015-11-18 |
2020-01-30 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
EP3377107B1
(en)
|
2015-11-19 |
2020-08-12 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
RU2018123717A
(ru)
|
2015-12-01 |
2020-01-14 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Комбинированные лечения, их применения и способы
|
|
CR20180286A
(es)
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
MA44082A
(fr)
|
2015-12-14 |
2018-10-24 |
Macrogenics Inc |
Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
|
|
KR102738306B1
(ko)
|
2015-12-15 |
2024-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
Cxcr4 수용체 길항제
|
|
PT3389699T
(pt)
|
2015-12-15 |
2024-06-04 |
Oncoc4 Inc |
Anticorpos monoclonais quiméricos e humanizados anti-ctla4 humano e utilizações dos mesmos
|
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3390454A4
(en)
|
2015-12-17 |
2019-08-28 |
University of Maryland, Baltimore County |
RECOMBINANT BISPEZIFIC POLYPEPTIDE FOR THE COORDINATED ACTIVATION OF TUMOR REACTIVE T CELLS AND FOR THE NEUTRALIZATION OF IMMUNOSUPPRESSION
|
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
ＣＤ３２ｂを標的とする抗体およびその使用方法
|
|
JP2019505575A
(ja)
|
2015-12-21 |
2019-02-28 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
部位特異的な結合のための変異型抗体
|
|
PT3394103T
(pt)
|
2015-12-22 |
2023-09-04 |
Regeneron Pharma |
Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
|
|
EP4643874A2
(en)
|
2015-12-22 |
2025-11-05 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
LT3394033T
(lt)
|
2015-12-22 |
2021-03-10 |
Incyte Corporation |
Heterocikliniai junginiai, kaip imunomoduliatoriai
|
|
HRP20220525T1
(hr)
|
2015-12-23 |
2022-05-27 |
Modernatx, Inc. |
Postupci uporabe polinukleotida koji kodiraju ligand ox40
|
|
CN105461808B
(zh)
*
|
2015-12-24 |
2019-03-19 |
长春金赛药业股份有限公司 |
单克隆抗体及其应用
|
|
EP3400443B1
(en)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
CN106939047B
(zh)
*
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
MX382150B
(es)
|
2016-01-08 |
2025-03-13 |
Celgene Corp |
Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
|
|
TWI782395B
(zh)
|
2016-01-08 |
2022-11-01 |
美商西建公司 |
抗增生化合物，及其醫藥組合物及用途
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
MX385964B
(es)
|
2016-01-08 |
2025-03-18 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
|
|
US20190008869A1
(en)
|
2016-01-13 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
|
|
HUE054356T2
(hu)
|
2016-01-21 |
2021-09-28 |
Innate Pharma |
Gátlási reakcióutak semlegesítése limfocitákban
|
|
EP3405497A2
(en)
*
|
2016-01-22 |
2018-11-28 |
Mabquest SA |
Immunological reagents
|
|
KR20180104036A
(ko)
|
2016-01-22 |
2018-09-19 |
머크 샤프 앤드 돔 코포레이션 |
항-응고 인자 xi 항체
|
|
JP6970099B2
(ja)
|
2016-01-28 |
2021-11-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置のための方法及び医薬組成物
|
|
US10822415B2
(en)
|
2016-01-28 |
2020-11-03 |
Inserm (Institut National De La Santéet De La Recherche Médicale) |
Methods for enhancing the potency of the immune checkpoint inhibitors
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
CA3013554A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Targeted therapeutic agents and uses thereof
|
|
JP7014724B2
(ja)
|
2016-02-06 |
2022-02-01 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
タンデム型Ｆａｂ免疫グロブリンおよびその使用
|
|
RU2753543C1
(ru)
|
2016-02-08 |
2021-08-17 |
Бейондспринг Фармасьютикалс, Инк. |
Композиции, содержащие тукаресол или его аналоги
|
|
US9845325B2
(en)
|
2016-02-19 |
2017-12-19 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
CA3013333A1
(en)
|
2016-02-26 |
2017-08-31 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10465014B2
(en)
*
|
2016-03-04 |
2019-11-05 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
|
|
US20200281973A1
(en)
|
2016-03-04 |
2020-09-10 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
US20170252417A1
(en)
|
2016-03-07 |
2017-09-07 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
WO2017153433A1
(en)
|
2016-03-08 |
2017-09-14 |
Innate Pharma |
Siglec neutralizing antibodies
|
|
JP7208492B2
(ja)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー， インコーポレイテッド |
併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
RU2744959C2
(ru)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
Новые анти-pd-l1 антитела
|
|
PT3433257T
(pt)
|
2016-03-24 |
2023-11-29 |
Novartis Ag |
Análogos nucleosídeos de alquinil como inibidores do rinovírus humano
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3436070A4
(en)
|
2016-03-29 |
2019-11-27 |
University of Southern California |
AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
|
|
WO2017167921A1
(en)
|
2016-03-30 |
2017-10-05 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
JP6746712B2
(ja)
|
2016-04-07 |
2020-08-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節因子として有用な複素環式アミド
|
|
EP3440072B1
(en)
|
2016-04-07 |
2020-01-29 |
GlaxoSmithKline Intellectual Property Development Ltd |
Heterocyclic amides useful as protein modulators
|
|
US20170306050A1
(en)
|
2016-04-08 |
2017-10-26 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
|
RU2747788C2
(ru)
|
2016-04-12 |
2021-05-14 |
Эли Лилли Энд Компани |
Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
|
|
EP3442528B1
(en)
|
2016-04-12 |
2021-05-26 |
Eli Lilly and Company |
Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
|
|
KR102466763B1
(ko)
|
2016-04-13 |
2022-11-11 |
오리맵스 리미티드 |
항- psma 항체 및 이의 용도
|
|
CN109789195A
(zh)
|
2016-04-13 |
2019-05-21 |
维维雅生物技术公司 |
离体bite激活的t细胞
|
|
SMT202400438T1
(it)
|
2016-04-14 |
2024-11-15 |
Ose Immunotherapeutics |
Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
|
|
WO2017181111A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
KR20190003957A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암 모니터링 및 치료 방법
|
|
US10865244B2
(en)
|
2016-04-18 |
2020-12-15 |
Celldex Therapeutics, Inc. |
Nucleic acids encoding agonistic antibodies that bind CD40
|
|
EP3449921B1
(en)
|
2016-04-28 |
2023-05-31 |
Eisai R&D Management Co., Ltd. |
Eribulin for inhibiting tumor growth
|
|
CA3021645A1
(en)
|
2016-04-29 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
|
|
EP3452451A4
(en)
|
2016-05-04 |
2019-11-13 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
JP2019522627A
(ja)
|
2016-05-04 |
2019-08-15 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
CN109414421A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
MX2018013519A
(es)
|
2016-05-05 |
2019-03-14 |
Glaxosmithkline Ip No 2 Ltd |
Inhibidores del potenciador del homologo zeste 2.
|
|
WO2017196598A1
(en)
|
2016-05-10 |
2017-11-16 |
Bristol-Myers Squibb Company |
Antibody-drug conjugates of tubulysin analogs with enhanced stability
|
|
WO2017194782A2
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
CN109689087B
(zh)
|
2016-05-13 |
2023-04-04 |
奥里尼斯生物科学私人有限公司 |
靶向性突变干扰素-β及其用途
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
PT3458474T
(pt)
|
2016-05-18 |
2022-11-08 |
Modernatx Inc |
Combinações de arnm que codificam polipéptidos de modulação imunitária e as suas utilizações
|
|
WO2017201281A1
(en)
|
2016-05-18 |
2017-11-23 |
Mayo Foundation For Medical Education And Research |
Targeting pd-l1 on tumor cells
|
|
CN109195621A
(zh)
|
2016-05-18 |
2019-01-11 |
莫得纳特斯公司 |
编码白细胞介素12(il12)的多核苷酸及其用途
|
|
JP7194022B2
(ja)
|
2016-05-20 |
2022-12-21 |
イーライ リリー アンド カンパニー |
Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
|
|
CN105968200B
(zh)
*
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
JP7014736B2
(ja)
|
2016-05-24 |
2022-02-01 |
ジェネンテック， インコーポレイテッド |
がんの処置のためのピラゾロピリジン誘導体
|
|
CN115028617A
(zh)
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
JP7563872B2
(ja)
|
2016-05-25 |
2024-10-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
癌を処置するための方法及び組成物
|
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
JP7016323B2
(ja)
|
2016-06-01 |
2022-02-21 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
|
|
KR20230119265A
(ko)
|
2016-06-02 |
2023-08-16 |
브리스톨-마이어스 스큅 컴퍼니 |
림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
HUE065176T2
(hu)
|
2016-06-02 |
2024-05-28 |
Ultimovacs Asa |
Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
|
|
HRP20230864T1
(hr)
|
2016-06-02 |
2023-11-10 |
Bristol-Myers Squibb Company |
Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
|
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
|
KR20190015408A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
|
|
WO2017210637A1
(en)
|
2016-06-03 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
|
|
EP3463337A4
(en)
|
2016-06-06 |
2020-02-12 |
Beyondspring Pharmaceuticals, Inc. |
COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
|
|
JP2019521109A
(ja)
|
2016-06-08 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパテ |
化学化合物
|
|
ES2913929T3
(es)
|
2016-06-08 |
2022-06-06 |
Glaxosmithkline Ip Dev Ltd |
Compuestos químicos como inhibidores de la ruta de ATF4
|
|
AU2017284632B2
(en)
*
|
2016-06-13 |
2020-05-14 |
I-Mab Biopharma Co., Ltd. |
Anti-PD-L1 antibodies and uses thereof
|
|
CN107488229B
(zh)
*
|
2016-06-13 |
2020-11-17 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
|
US11472856B2
(en)
|
2016-06-13 |
2022-10-18 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
MA45250B1
(fr)
|
2016-06-14 |
2020-09-30 |
Novartis Ag |
Forme crystalline de (r)-4-(5-(cyclopropyléthynyl)isoxazol-3-yl)-n-hydroxy-2-méthyl-2-(méthylsulfonyl)butanamide en tant qu'agent antibacteriel
|
|
TWI802193B
(zh)
|
2016-06-14 |
2023-05-11 |
美商默沙東有限責任公司 |
抗凝血因子ｘｉ抗體
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
SI3472207T1
(sl)
*
|
2016-06-20 |
2021-04-30 |
F-Star Delta Limited |
Vezavne molekule, ki vežejo PD-L1 in LAG-3
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
HRP20221030T1
(hr)
|
2016-06-20 |
2022-11-11 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
RU2018142573A
(ru)
|
2016-06-20 |
2020-07-21 |
Ф-Стар Бета Лимитед |
Партнеры по связыванию lag-3
|
|
WO2017220602A1
(en)
|
2016-06-21 |
2017-12-28 |
Herlev Hospital |
Pdl1 peptides for use in cancer vaccines
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
CA3027204A1
(en)
*
|
2016-06-29 |
2018-01-04 |
Checkpoint Therapeutics, Inc. |
Pd-l1-specific antibodies and methods of using the same
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
AU2017293423B2
(en)
|
2016-07-05 |
2023-05-25 |
Beone Medicines I Gmbh |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
EP3481866B1
(en)
*
|
2016-07-06 |
2024-07-24 |
Bristol-Myers Squibb Company |
Combination of tim-4 antagonist and pd-1 antagonist and methods of use
|
|
ES3000676T3
(en)
|
2016-07-07 |
2025-03-03 |
Iovance Biotherapeutics Inc |
Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
EP4512829A3
(en)
|
2016-07-14 |
2025-06-11 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
|
AU2017300123A1
(en)
|
2016-07-20 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as PERK inhibitors
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
EP3490676A1
(en)
|
2016-07-29 |
2019-06-05 |
Eli Lilly and Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
|
JP2019527236A
(ja)
|
2016-08-01 |
2019-09-26 |
モレキュラー テンプレーツ，インコーポレイティド |
癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
|
|
WO2018027039A1
(en)
|
2016-08-03 |
2018-02-08 |
Nextcure, Inc. |
Compositions and methods for modulating lair signal transduction
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
US10919966B2
(en)
|
2016-08-05 |
2021-02-16 |
Y-Biologics Inc. |
Antibody to programmed death-ligand 1 (PD-L1) and use thereof
|
|
WO2018026249A1
(ko)
*
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
CN117736325A
(zh)
|
2016-08-09 |
2024-03-22 |
科马布有限公司 |
分离抗体及其应用
|
|
EP3511340B1
(en)
|
2016-08-10 |
2024-10-02 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
BR112019001818A2
(pt)
|
2016-08-12 |
2019-05-07 |
Merck Patent Gmbh |
terapia combinada para câncer
|
|
MX2019001635A
(es)
|
2016-08-12 |
2019-06-10 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
|
|
EP3498838A4
(en)
*
|
2016-08-15 |
2020-01-08 |
National University Corporation Hokkaido University |
ANTI-PD-L1 ANTIBODY
|
|
AU2017313085B2
(en)
|
2016-08-19 |
2024-06-20 |
Beone Medicines I Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
WO2018035391A1
(en)
|
2016-08-19 |
2018-02-22 |
Bristol-Myers Squibb Company |
Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
JP2019528300A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
|
|
WO2018045177A1
(en)
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
|
CN106248955A
(zh)
*
|
2016-09-03 |
2016-12-21 |
长春工业大学 |
一种检测人源化pd‑l1抗体的试剂盒
|
|
US11096924B2
(en)
|
2016-09-07 |
2021-08-24 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and PGE2 antagonists
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
JP2019526595A
(ja)
|
2016-09-09 |
2019-09-19 |
ティージー セラピューティクス，インコーポレイテッド |
血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ
|
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
EP3512563A1
(en)
|
2016-09-16 |
2019-07-24 |
The Johns Hopkins University |
Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
|
|
ES2977137T3
(es)
|
2016-09-16 |
2024-08-19 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-PD-1
|
|
IL265485B2
(en)
*
|
2016-09-20 |
2024-07-01 |
Pfizer |
Diagnostic anti-PD-L1 antibody and its use
|
|
JP6908710B2
(ja)
|
2016-09-21 |
2021-07-28 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用
|
|
JP7069177B2
(ja)
|
2016-09-21 |
2022-05-17 |
ネクストキュア インコーポレイテッド |
シグレック－１５に対する抗体及びその使用方法
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
WO2018055080A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
US11673971B2
(en)
|
2016-09-23 |
2023-06-13 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
JP7089507B2
(ja)
|
2016-09-26 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－１軸阻害剤への応答を予測すること
|
|
EP3519827A1
(en)
|
2016-09-27 |
2019-08-07 |
Oncologie, Inc. |
Methods for treating cancer with bavituximab based on levels of 2-glycoprotein 1, and assays therefor
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
CA3038671A1
(en)
|
2016-09-29 |
2018-04-05 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
|
|
GEP20217285B
(en)
|
2016-10-04 |
2021-08-10 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
|
EP4541423A3
(en)
|
2016-10-06 |
2025-06-25 |
Pfizer Inc. |
Dosing regimen of avelumab for the treatment of cancer
|
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
AU2017342176A1
(en)
|
2016-10-10 |
2019-05-02 |
The National Institute for Biotechnology in the Negev Ltd. |
Non-cytotoxic modified cells and use thereof
|
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
US11376259B2
(en)
|
2016-10-12 |
2022-07-05 |
Eli Lilly And Company |
Targeted treatment of mature T-cell lymphoma
|
|
US20190263927A1
(en)
|
2016-10-14 |
2019-08-29 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
WO2018075842A1
(en)
|
2016-10-20 |
2018-04-26 |
Bristol-Myers Squibb Company |
Condensed benzodiazepine derivatives and conjugates made therefrom
|
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
IL266209B2
(en)
|
2016-10-26 |
2025-02-01 |
Iovance Biotherapeutics Inc |
Re-stimulation of cryopreserved infiltrating lymphocytes
|
|
CN106478819B
(zh)
*
|
2016-10-27 |
2018-12-07 |
常州费洛斯药业科技有限公司 |
一种针对pd-l1的单克隆抗体或抗体片段
|
|
CN107987153A
(zh)
*
|
2016-10-27 |
2018-05-04 |
广东香雪精准医疗技术有限公司 |
高亲和力的可溶性pd-1分子
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
CN110099925A
(zh)
|
2016-10-28 |
2019-08-06 |
百时美施贵宝公司 |
使用抗pd-1抗体治疗尿道上皮癌的方法
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
KR102543323B1
(ko)
*
|
2016-10-30 |
2023-06-14 |
상하이 헨리우스 바이오테크, 인크. |
항-pd-l1 항체 및 변이체
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
AU2017355446A1
(en)
|
2016-11-03 |
2019-05-02 |
Bristol-Myers Squibb Company |
Activatable anti-CTLA-4 antibodies and uses thereof
|
|
US10342785B2
(en)
|
2016-11-04 |
2019-07-09 |
Askat Inc. |
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
|
|
KR102526034B1
(ko)
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
|
WO2018094167A1
(en)
|
2016-11-17 |
2018-05-24 |
Iovance Biotherapeutics, Inc. |
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
CN106496327B
(zh)
*
|
2016-11-18 |
2019-01-15 |
昆山百尔泰生物科技有限公司 |
针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
|
|
EP3541825A1
(en)
|
2016-11-21 |
2019-09-25 |
Idenix Pharmaceuticals LLC. |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
CN110662552A
(zh)
|
2016-11-30 |
2020-01-07 |
昂科梅德制药有限公司 |
包含tigit结合剂的癌症治疗方法
|
|
JP2020500878A
(ja)
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
US10736976B2
(en)
|
2016-12-01 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
|
|
CN110234342A
(zh)
|
2016-12-01 |
2019-09-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
组合疗法
|
|
KR20190104529A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포의 조절 방법
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
AU2017373945B2
(en)
|
2016-12-07 |
2025-01-23 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
US11013802B2
(en)
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
WO2018106895A1
(en)
|
2016-12-07 |
2018-06-14 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
US12168008B2
(en)
|
2016-12-08 |
2024-12-17 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
KR20190095921A
(ko)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
|
BR112019012154A2
(pt)
|
2016-12-14 |
2019-11-12 |
Janssen Biotech Inc |
domínios do tipo iii da fibronectina de ligação a cd8a
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
CN108218987B
(zh)
*
|
2016-12-21 |
2019-08-20 |
南京金斯瑞生物科技有限公司 |
高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人ctla4抗体
|
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
BR112019012993A2
(pt)
|
2016-12-22 |
2019-12-03 |
Incyte Corporation |
derivados de benzo-oxazol como imunomoduladores
|
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
CA3047508A1
(en)
|
2016-12-23 |
2018-06-28 |
Virttu Biologics Limited |
Treatment of cancer
|
|
EP3559045A4
(en)
*
|
2016-12-23 |
2020-08-19 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
|
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
|
KR102679324B1
(ko)
|
2017-01-05 |
2024-06-28 |
네트리 파르마 |
네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
WO2018129381A1
(en)
|
2017-01-06 |
2018-07-12 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
WO2018129497A1
(en)
|
2017-01-09 |
2018-07-12 |
Bioxcel Therapeutics, Inc. |
Predictive and diagnostic methods for prostate cancer
|
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3568466A4
(en)
|
2017-01-10 |
2020-07-15 |
The General Hospital Corporation |
TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
|
|
KR20190103226A
(ko)
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
SG11201905812WA
(en)
|
2017-01-20 |
2019-08-27 |
Arcus Biosciences Inc |
Azolopyrimidine for the treatment of cancer-related disorders
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
JP7082424B2
(ja)
|
2017-01-25 |
2022-06-08 |
モレキュラー テンプレーツ，インク． |
脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
|
|
WO2018138685A2
(en)
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
EP3573717B1
(en)
|
2017-01-27 |
2021-07-28 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
SG11201907023UA
(en)
|
2017-02-01 |
2019-08-27 |
Beyondspring Pharmaceuticals Inc |
Method of reducing neutropenia
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3577138A1
(en)
|
2017-02-06 |
2019-12-11 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
|
KR102572663B1
(ko)
|
2017-02-08 |
2023-09-01 |
노파르티스 아게 |
Fgf21 모방 항체 및 이의 용도
|
|
WO2018146612A1
(en)
|
2017-02-10 |
2018-08-16 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
EP3583127B1
(en)
|
2017-02-16 |
2024-11-20 |
Ying Zhang |
Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
|
IL268479B2
(en)
|
2017-02-21 |
2024-06-01 |
Regeneron Pharma |
Anti-PD-1 antibodies for the treatment of lung cancer
|
|
CA3053803A1
(en)
|
2017-02-24 |
2018-08-30 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
RU2019126627A
(ru)
|
2017-02-27 |
2021-03-29 |
Новартис Аг |
Схема введения доз комбинации церитиниба и молекулы антитела к pd-1
|
|
CA3052767A1
(en)
|
2017-02-27 |
2018-08-30 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
AU2018228873A1
(en)
|
2017-03-01 |
2019-08-29 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3372615A1
(en)
*
|
2017-03-06 |
2018-09-12 |
Merck Patent GmbH |
Composition comprising avelumab
|
|
LT3592769T
(lt)
|
2017-03-09 |
2024-08-26 |
Genmab A/S |
Antikūnai, atpažįstantys pd-l1
|
|
SG10202110182PA
(en)
|
2017-03-15 |
2021-10-28 |
Silverback Therapeutics Inc |
Benzazepine compounds, conjugates, and uses thereof
|
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
|
EP3595690A1
(en)
|
2017-03-15 |
2020-01-22 |
Amgen Inc. |
Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
|
|
WO2018167267A1
(en)
|
2017-03-16 |
2018-09-20 |
Innate Pharma |
Compositions and methods for treating cancer
|
|
CA3056700A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Nantomics, Llc |
Liquid biopsy for cfrna
|
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
KR102644408B1
(ko)
|
2017-03-30 |
2024-03-07 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
|
|
AU2018244935A1
(en)
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
CN110709392B
(zh)
|
2017-03-30 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的异喹啉
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
EP3606960A1
(en)
|
2017-04-03 |
2020-02-12 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
RU2740438C1
(ru)
*
|
2017-04-05 |
2021-01-14 |
Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи |
Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их
|
|
EP4516809A3
(en)
|
2017-04-05 |
2025-09-03 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
TW201839400A
(zh)
|
2017-04-14 |
2018-11-01 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
|
RU2665790C1
(ru)
*
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
WO2018195123A1
(en)
|
2017-04-18 |
2018-10-25 |
Tempest Therapeutics, Inc. |
Bicyclic compounds and their use in the treatment of cancer
|
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス， インコーポレイテッド |
多重特異性分子およびその使用
|
|
CN106939049B
(zh)
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
|
CN110582303A
(zh)
|
2017-04-20 |
2019-12-17 |
Adc治疗有限公司 |
使用抗cd25抗体-药物缀合物的组合疗法
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
PL3612234T3
(pl)
|
2017-04-20 |
2024-09-02 |
Adc Therapeutics Sa |
Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
|
|
US10570138B2
(en)
|
2017-04-21 |
2020-02-25 |
Kyn Therapeutics |
Indole AHR inhibitors and uses thereof
|
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ジスルフィド結合の還元を最小限にする抗体製造法
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN110678750A
(zh)
|
2017-04-28 |
2020-01-10 |
美国默沙东药厂 |
用于癌症治疗的生物标志物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3615566B1
(en)
|
2017-04-28 |
2023-12-20 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
|
CN108864290B
(zh)
|
2017-05-08 |
2021-12-07 |
上海津曼特生物科技有限公司 |
双特异性重组蛋白及其应用
|
|
CN121159691A
(zh)
|
2017-05-12 |
2025-12-19 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7263256B6
(ja)
*
|
2017-05-16 |
2023-07-24 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｐｄ－ｌ１抗体医薬組成物およびその使用
|
|
US11359014B2
(en)
*
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
JP7189155B2
(ja)
|
2017-05-17 |
2022-12-13 |
アーカス バイオサイエンシズ インコーポレイティド |
癌関連障害の治療のためのキナゾリン－ピラゾール誘導体
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
US12006354B2
(en)
|
2017-05-24 |
2024-06-11 |
Novartis Ag |
Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
|
|
EP3630833A1
(en)
|
2017-05-25 |
2020-04-08 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
IL322104A
(en)
|
2017-05-30 |
2025-09-01 |
Bristol Myers Squibb Co |
Treatment of lag-3 positive tumors
|
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
|
WO2018222722A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
EP3630834A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
CN110678483B
(zh)
|
2017-06-01 |
2023-09-22 |
百时美施贵宝公司 |
用抗pd-1抗体治疗肿瘤的方法
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
CA3065929A1
(en)
|
2017-06-01 |
2018-12-06 |
Michael Wayne SAVILLE |
Bispecific antibodies that bind cd123 and cd3
|
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー．， インコーポレイテッド |
Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
EP3634483A1
(en)
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
EP4461825A3
(en)
|
2017-06-09 |
2024-11-20 |
Providence Health & Services - Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
BR112019026564A2
(pt)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd19
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
US20200147099A1
(en)
|
2017-06-20 |
2020-05-14 |
Institut Curie |
Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EA202090103A1
(ru)
|
2017-06-22 |
2020-04-24 |
Селджин Корпорейшн |
Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
|
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
|
KR102735038B1
(ko)
|
2017-06-23 |
2024-11-28 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1의 길항제로서 작용하는 면역조정제
|
|
CN110799543A
(zh)
|
2017-06-26 |
2020-02-14 |
百济神州有限公司 |
肝细胞癌的免疫治疗
|
|
AU2018291081B2
(en)
|
2017-06-27 |
2025-02-20 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
WO2019006427A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
|
|
IL271601B2
(en)
|
2017-06-30 |
2024-05-01 |
Bristol Myers Squibb Co |
Amorphous and crystalline forms of ido inhibitors
|
|
EP3644999B1
(en)
|
2017-06-30 |
2022-12-14 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
|
|
CA3068395A1
(en)
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
CN111263769B
(zh)
|
2017-07-10 |
2024-01-02 |
先天制药公司 |
Siglec-9中和性抗体
|
|
KR102656934B1
(ko)
|
2017-07-10 |
2024-04-16 |
셀진 코포레이션 |
항증식성 화합물 및 이의 사용 방법
|
|
CN107266572A
(zh)
*
|
2017-07-13 |
2017-10-20 |
无锡傲锐东源生物科技有限公司 |
抗pd‑l1蛋白单克隆抗体及其用途
|
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
EP3655542A1
(en)
|
2017-07-18 |
2020-05-27 |
Institut Gustave Roussy |
Method for assessing the response to pd-1/pdl-1 targeting drugs
|
|
IL319798A
(en)
|
2017-07-20 |
2025-05-01 |
Novartis Ag |
ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
|
|
MX2020000604A
(es)
|
2017-07-21 |
2020-09-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
CN111148996A
(zh)
|
2017-07-28 |
2020-05-12 |
百时美施贵宝公司 |
用于检查点抑制剂的预测性外周血生物标志物
|
|
MX2020001233A
(es)
|
2017-08-03 |
2020-07-20 |
Otsuka Pharma Co Ltd |
Compuesto farmaceutico y metodos de purificacion del mismo.
|
|
CN111406067B
(zh)
|
2017-08-04 |
2022-11-08 |
健玛保 |
与pd-l1和cd137结合的结合剂及其用途
|
|
MA49773A
(fr)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme |
Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
|
|
EP3661948B1
(en)
|
2017-08-04 |
2022-06-01 |
BicycleTx Limited |
Bicyclic peptide ligands specific for cd137
|
|
AU2018311966A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Benzo[b]thiophene sting agonists for cancer treatment
|
|
JP2020530003A
(ja)
|
2017-08-07 |
2020-10-15 |
アムジェン インコーポレイテッド |
抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
JP7269917B2
(ja)
|
2017-08-17 |
2023-05-09 |
イケナ オンコロジー， インコーポレイテッド |
Ａｈｒ阻害剤およびその使用
|
|
TWI870011B
(zh)
|
2017-08-25 |
2025-01-11 |
美商戊瑞治療有限公司 |
Ｂ７－ｈ４抗體及其使用方法
|
|
KR20200044899A
(ko)
|
2017-08-28 |
2020-04-29 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료 및 진단을 위한 tim-3 길항제
|
|
MA50084A
(fr)
|
2017-09-04 |
2020-07-15 |
Agenus Inc |
Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
US11021540B2
(en)
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US20210060158A1
(en)
|
2017-09-19 |
2021-03-04 |
Institut Curie |
Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
EP3692033A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
|
AU2018346447B2
(en)
|
2017-10-06 |
2025-06-19 |
Innate Pharma |
Restoration of T cell activity via the CD39/CD73 axis
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
WO2019072868A1
(en)
|
2017-10-10 |
2019-04-18 |
Numab Therapeutics AG |
MULTISPECIFIC ANTIBODIES
|
|
CA3075337A1
(en)
|
2017-10-10 |
2019-04-18 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
|
EP4116327A1
(en)
*
|
2017-10-11 |
2023-01-11 |
Board Of Regents, The University Of Texas System |
Human pd-l1 antibodies and methods of use therefor
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CN111511766B
(zh)
|
2017-10-13 |
2024-06-07 |
Ose免疫疗法 |
修饰的抗SIRPa抗体及其应用
|
|
EA202090817A1
(ru)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
Триспецифические белки и способы их применения
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2019077062A1
(en)
|
2017-10-18 |
2019-04-25 |
Vivia Biotech, S.L. |
C-CELLS ACTIVATED BY BIT
|
|
SG11202003078VA
(en)
|
2017-10-18 |
2020-05-28 |
Alpine Immune Sciences Inc |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
|
CN111655725A
(zh)
|
2017-10-19 |
2020-09-11 |
德比奥药物国际股份有限公司 |
用于治疗癌症的组合产品
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
EP3703692B1
(en)
|
2017-11-01 |
2025-07-23 |
Merck Sharp & Dohme LLC |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
KR20200074214A
(ko)
|
2017-11-01 |
2020-06-24 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
|
|
KR20200084880A
(ko)
|
2017-11-06 |
2020-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
|
BR112020008812A2
(pt)
|
2017-11-06 |
2020-10-27 |
Juno Therapeutics Inc |
combinação de terapia celular e um inibidor de gama secretase
|
|
ES2939112T3
(es)
|
2017-11-10 |
2023-04-19 |
Armo Biosciences Inc |
Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
|
|
SG11202003477QA
(en)
|
2017-11-14 |
2020-05-28 |
Pfizer |
Ezh2 inhibitor combination therapies
|
|
EP3709986B1
(en)
|
2017-11-14 |
2023-11-01 |
Merck Sharp & Dohme LLC |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
KR102718287B1
(ko)
|
2017-11-14 |
2024-10-16 |
머크 샤프 앤드 돔 엘엘씨 |
인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 비아릴 화합물
|
|
MX2020004967A
(es)
|
2017-11-17 |
2020-08-27 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
|
|
WO2019097479A1
(en)
|
2017-11-17 |
2019-05-23 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
CA3082409A1
(en)
|
2017-11-17 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
|
|
US11679148B2
(en)
|
2017-11-24 |
2023-06-20 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods and compositions for treating cancers
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019109974A1
(zh)
*
|
2017-12-06 |
2019-06-13 |
正大天晴药业集团南京顺欣制药有限公司 |
抗pd-l1抗体及其抗原结合片段
|
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
ES2927194T3
(es)
|
2017-12-15 |
2022-11-03 |
Janssen Biotech Inc |
Dinucleótidos cíclicos como agonistas de STING
|
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
|
CN111741976B
(zh)
|
2017-12-19 |
2024-09-17 |
英沃克斯制药有限公司 |
包括pd-l1抗原结合位点的fc结合片段
|
|
MX2020006372A
(es)
|
2017-12-19 |
2020-09-03 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada.
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN111433210A
(zh)
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
CN109970857B
(zh)
*
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
KR102813744B1
(ko)
|
2017-12-27 |
2025-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
|
US11571427B2
(en)
|
2017-12-28 |
2023-02-07 |
The General Hospital Corporation |
Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
|
|
TWI864129B
(zh)
*
|
2017-12-29 |
2024-12-01 |
圓祥生技股份有限公司 |
調節免疫檢查點作為癌症治療的單特異性蛋白質、其醫藥組成物、其核酸、及其用途
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
JP2021509586A
(ja)
|
2018-01-08 |
2021-04-01 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍抗原特異的ｔ細胞について濃縮されたｔｉｌ製品を生成するためのプロセス
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3087105A1
(en)
*
|
2018-01-10 |
2019-07-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
|
JP2021510733A
(ja)
|
2018-01-12 |
2021-04-30 |
ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737696A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
WO2019143607A1
(en)
|
2018-01-16 |
2019-07-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
WO2019143884A1
(en)
*
|
2018-01-19 |
2019-07-25 |
Vanderbilt University |
Conserved hiv antibody clonotypes and methods of use
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
EP3743076A1
(en)
|
2018-01-22 |
2020-12-02 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
AU2019210332A1
(en)
|
2018-01-22 |
2020-09-10 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
WO2019147670A1
(en)
|
2018-01-23 |
2019-08-01 |
Nextcure, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
BR112020014960A2
(pt)
|
2018-01-24 |
2020-12-22 |
Beyondspring Pharmaceuticals, Inc. |
Composição e método para redução de trombocitopenia
|
|
WO2019148089A1
(en)
|
2018-01-26 |
2019-08-01 |
Orionis Biosciences Inc. |
Xcr1 binding agents and uses thereof
|
|
MX2020007797A
(es)
|
2018-01-29 |
2020-09-18 |
Merck Patent Gmbh |
Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
|
|
SG11202006701TA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
AU2019214193B2
(en)
|
2018-02-05 |
2022-06-16 |
Foshan Ionova Biotherapeutics Co., Inc. |
Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
NL2020422B1
(en)
|
2018-02-12 |
2019-08-19 |
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis |
Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
|
|
CN118084940A
(zh)
|
2018-02-13 |
2024-05-28 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP7417527B2
(ja)
|
2018-02-16 |
2024-01-18 |
アーカス バイオサイエンシズ インコーポレイティド |
アゾロピリミジン化合物による投薬
|
|
EP3756012A1
(en)
|
2018-02-21 |
2020-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
CN111741978A
(zh)
|
2018-02-21 |
2020-10-02 |
戊瑞治疗有限公司 |
B7-h4抗体制剂
|
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
|
SG11202007678QA
(en)
|
2018-02-23 |
2020-09-29 |
Bicycletx Ltd |
Multimeric bicyclic peptide ligands
|
|
WO2019165434A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
CA3092470A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
JP2021515806A
(ja)
|
2018-03-02 |
2021-06-24 |
シーディアール−ライフ・アクチェンゲゼルシャフトＣｄｒ−Ｌｉｆｅ Ａｇ |
三重特異性抗原結合タンパク質
|
|
SG11202008113RA
(en)
|
2018-03-05 |
2020-09-29 |
Arcus Biosciences Inc |
Arginase inhibitors
|
|
CN111867679A
(zh)
|
2018-03-06 |
2020-10-30 |
居里研究所 |
用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
|
|
RU2020133451A
(ru)
|
2018-03-12 |
2022-04-12 |
Инститьют Насьонал Де Ла Санте Et De La Решерш Медикаль (Инсерм) |
Применение терапевтически эффективной комбинации химиотерапиии и ингибитора контрольной точки иммунного ответа с миметиком ограничения калорийности для лечения рака
|
|
CN112105646A
(zh)
|
2018-03-13 |
2020-12-18 |
Ose免疫疗法 |
抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法
|
|
EP3765006A4
(en)
|
2018-03-13 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
ARGINASE INHIBITORS AND METHODS OF USE
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765019A1
(en)
|
2018-03-14 |
2021-01-20 |
Merck Patent GmbH |
Compounds and uses thereof to treat tumors in a subject
|
|
US10738128B2
(en)
|
2018-03-14 |
2020-08-11 |
Surface Oncology, Inc. |
Antibodies that bind CD39 and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2021518380A
(ja)
*
|
2018-03-19 |
2021-08-02 |
アベオメ コーポレーション |
プログラム細胞死リガンド１（ｐｄ−ｌ１）に対する高親和性中和モノクローナル抗体、及びその使用
|
|
WO2019179400A1
(en)
*
|
2018-03-21 |
2019-09-26 |
China Medical University |
Engineering stem cells for cancer therapy
|
|
KR102874694B1
(ko)
|
2018-03-21 |
2025-10-23 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
KR102879521B1
(ko)
|
2018-03-22 |
2025-11-03 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
CN119101158A
(zh)
|
2018-03-23 |
2024-12-10 |
得克萨斯州大学系统董事会 |
人pd-l2抗体及其使用方法
|
|
EP4501355A3
(en)
|
2018-03-23 |
2025-04-30 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
|
CN117586412A
(zh)
|
2018-03-23 |
2024-02-23 |
得克萨斯州大学系统董事会 |
针对人pd-l1和pd-l2的双重特异性抗体及其使用方法
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
JP2021519284A
(ja)
*
|
2018-03-27 |
2021-08-10 |
ラボラトリー コーポレイション オブ アメリカ ホールディングス |
治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ
|
|
CA3095076A1
(en)
*
|
2018-03-29 |
2019-10-03 |
Adagene Inc. |
Anti-pd-l1 antibodies and use thereof
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
EP4386080A3
(en)
|
2018-03-29 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
MY210070A
(en)
|
2018-03-30 |
2025-08-25 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
US20210032344A1
(en)
|
2018-03-30 |
2021-02-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
MX2020010407A
(es)
|
2018-04-03 |
2020-10-22 |
Merck Sharp & Dohme |
Benzotiofenos y compuestos relacionados como agonistas de sting.
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
IL297847B2
(en)
*
|
2018-04-09 |
2024-02-01 |
Origincell Therapeutics Co Ltd |
Anti-PD-L1 antibody and its use
|
|
AU2019251421B2
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
KR20200142542A
(ko)
|
2018-04-12 |
2020-12-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
WO2019204132A1
(en)
*
|
2018-04-15 |
2019-10-24 |
Biosion Inc. |
Antibodies binding pd-1 and uses thereof
|
|
CN112292128A
(zh)
|
2018-04-16 |
2021-01-29 |
阿瑞斯医疗有限公司 |
Ep4抑制剂和其用途
|
|
WO2019201195A1
(zh)
|
2018-04-16 |
2019-10-24 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
AU2019255717B2
(en)
|
2018-04-17 |
2022-12-08 |
Tempest Therapeutics, Inc. |
Bicyclic carboxamides and methods of use thereof
|
|
WO2019204272A1
(en)
|
2018-04-17 |
2019-10-24 |
Molecular Templates, Inc. |
Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
|
AU2019255750B2
(en)
|
2018-04-19 |
2021-10-21 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
US10907161B2
(en)
|
2018-04-19 |
2021-02-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
|
WO2019204179A1
(en)
|
2018-04-20 |
2019-10-24 |
Merck Sharp & Dohme Corp. |
Novel substituted rig-i agonists: compositions and methods thereof
|
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
|
AU2019261582A1
(en)
|
2018-04-25 |
2020-11-12 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
CA3096909A1
(en)
|
2018-04-26 |
2019-10-31 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
CN112074541A
(zh)
|
2018-05-03 |
2020-12-11 |
上海岸迈生物科技有限公司 |
Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
|
|
US11466004B2
(en)
|
2018-05-04 |
2022-10-11 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
|
CN112566912A
(zh)
|
2018-05-04 |
2021-03-26 |
因赛特公司 |
Fgfr抑制剂的盐
|
|
WO2019211492A1
(en)
|
2018-05-04 |
2019-11-07 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
|
US20210246208A1
(en)
|
2018-05-04 |
2021-08-12 |
Merck Patent Gmbh |
Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancer
|
|
US12473532B2
(en)
|
2018-05-10 |
2025-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
PT3790877T
(pt)
|
2018-05-11 |
2023-05-10 |
Incyte Corp |
Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
|
|
KR20240165483A
(ko)
|
2018-05-14 |
2024-11-22 |
길리애드 사이언시즈, 인코포레이티드 |
Mcl-1 억제제
|
|
US12209126B2
(en)
|
2018-05-15 |
2025-01-28 |
Medimmune Limited |
Treatment of cancer
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
KR20210010998A
(ko)
*
|
2018-05-17 |
2021-01-29 |
난징 리즈 바이오랩스 씨오., 엘티디. |
항체 결합 피디 1 및 그의 용도
|
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
KR102718800B1
(ko)
|
2018-05-23 |
2024-10-18 |
셀진 코포레이션 |
다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
|
|
KR102813281B1
(ko)
|
2018-05-23 |
2025-05-28 |
셀진 코포레이션 |
병용 사용을 위한 bcma 및 cd3에 대한 항증식성 화합물 및 이중특이성 항체
|
|
KR20210016562A
(ko)
|
2018-05-23 |
2021-02-16 |
에이디씨 테라퓨틱스 에스에이 |
분자 애쥬번트
|
|
EA202092747A1
(ru)
|
2018-05-29 |
2021-03-16 |
Бристол-Маерс Сквибб Компани |
Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US12331068B2
(en)
|
2018-05-31 |
2025-06-17 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting CD73
|
|
MX2020012939A
(es)
|
2018-05-31 |
2021-02-15 |
Ono Pharmaceutical Co |
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
|
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2019276656A1
(en)
|
2018-06-01 |
2021-01-07 |
Novartis Ag |
Dosing of a bispecific antibody that bind CD123 and CD3
|
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
|
KR20210056288A
(ko)
*
|
2018-06-01 |
2021-05-18 |
타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 |
질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
|
|
EP3802579A1
(en)
|
2018-06-01 |
2021-04-14 |
The Board of Trustees of the Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
WO2019227490A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
CN112566938B
(zh)
|
2018-06-03 |
2025-04-01 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
|
CN110563842B
(zh)
|
2018-06-06 |
2022-07-29 |
浙江博锐生物制药有限公司 |
针对程序性死亡配体(pd-l1)的抗体及其应用
|
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
JP2021528393A
(ja)
|
2018-06-15 |
2021-10-21 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
後細胞シグナル伝達因子の調節による免疫活性の上昇
|
|
US11377503B2
(en)
|
2018-06-18 |
2022-07-05 |
Innate Pharma |
Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
|
|
CN112533629A
(zh)
|
2018-06-19 |
2021-03-19 |
阿尔莫生物科技股份有限公司 |
结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
|
|
IL279455B1
(en)
|
2018-06-20 |
2025-09-01 |
Incyte Corp |
ANTI-PD-1 ANTIBODIES AND THEIR USES
|
|
WO2019245890A1
(en)
|
2018-06-20 |
2019-12-26 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
CN112585166A
(zh)
|
2018-06-23 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
|
|
CN112654621B
(zh)
|
2018-06-27 |
2024-05-14 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|
|
EA202190137A1
(ru)
|
2018-06-27 |
2021-05-17 |
Бристол-Маерс Сквибб Компани |
Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
CN112513077B
(zh)
*
|
2018-07-09 |
2025-05-16 |
上海岸迈生物科技有限公司 |
高效表达的egfr和pd-l1双特异性结合蛋白
|
|
EP3820904A2
(en)
|
2018-07-09 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
|
CA3105942A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR112020026947B1
(pt)
|
2018-07-10 |
2022-11-22 |
Novartis Ag |
Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica
|
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
CN121203021A
(zh)
|
2018-07-11 |
2025-12-26 |
戊瑞治疗有限公司 |
在酸性pH下结合至VISTA的抗体
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
US12344672B2
(en)
|
2018-07-12 |
2025-07-01 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
MX2021000399A
(es)
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
KR102530517B1
(ko)
|
2018-07-13 |
2023-05-09 |
알렉터 엘엘씨 |
항-소틸린 항체 및 이들의 사용 방법
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
CA3106366A1
(en)
|
2018-07-18 |
2020-01-23 |
Arcus Biosciences, Inc. |
Solid forms of an azolopyrimidine compound
|
|
JP7072715B2
(ja)
|
2018-07-20 |
2022-05-20 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ１１２ｒ組成物及び方法
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3826721B1
(en)
|
2018-07-24 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Naphthyridine compounds and uses thereof
|
|
TW202019905A
(zh)
|
2018-07-24 |
2020-06-01 |
瑞士商赫孚孟拉羅股份公司 |
異喹啉化合物及其用途
|
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
JP2021532143A
(ja)
|
2018-07-26 |
2021-11-25 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の処置のためのｌａｇ−３併用療法
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
US20210236633A1
(en)
|
2018-08-06 |
2021-08-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
CN113307872B
(zh)
*
|
2018-08-11 |
2022-12-06 |
广东天科雅生物医药科技有限公司 |
一种工程化核酸、t细胞及其应用和产生方法
|
|
EP3837014B1
(en)
|
2018-08-16 |
2022-10-19 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
CA3109778A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
JP7488534B2
(ja)
*
|
2018-08-20 |
2024-05-22 |
１グローブ バイオメディカル カンパニー， リミテッド |
新規ながん免疫療法抗体組成物
|
|
CN112955221A
(zh)
|
2018-08-27 |
2021-06-11 |
皮里斯制药有限公司 |
包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
US20210340279A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP7654539B2
(ja)
|
2018-09-07 |
2025-04-01 |
ファイザー・インク |
抗αｖβ８抗体、組成物及びその使用
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
CN113164466B
(zh)
|
2018-09-11 |
2025-07-08 |
柯瑞斯公司 |
使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
AU2019339777B2
(en)
|
2018-09-12 |
2022-09-01 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
JP2022500404A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
|
|
US20200113912A1
(en)
|
2018-09-12 |
2020-04-16 |
Silverback Therapeutics, Inc. |
Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
|
|
US20220323596A1
(en)
|
2018-09-12 |
2022-10-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
|
EP3849606A4
(en)
|
2018-09-13 |
2022-06-29 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
CN109053891B
(zh)
*
|
2018-09-17 |
2021-12-21 |
苏州泓迅生物科技股份有限公司 |
一种抗pd-l1抗体及其制备方法和应用
|
|
CN113015526A
(zh)
|
2018-09-19 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
螺环2,3-二氢-7-氮杂吲哚化合物及其用途
|
|
WO2020061376A2
(en)
|
2018-09-19 |
2020-03-26 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック， インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
CA3114024A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
KR20210068478A
(ko)
|
2018-09-28 |
2021-06-09 |
메사추세츠 인스티튜트 오브 테크놀로지 |
콜라겐-국재화된 면역조정성 분자 및 그의 방법
|
|
BR112021005606A2
(pt)
|
2018-09-29 |
2021-06-22 |
Novartis Ag |
processo de produção de um composto para inibir a atividade de shp2
|
|
CN113454070A
(zh)
|
2018-09-30 |
2021-09-28 |
豪夫迈·罗氏有限公司 |
噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
|
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
TW202023558A
(zh)
|
2018-10-03 |
2020-07-01 |
美商建南德克公司 |
8-胺基異喹啉化合物及其用途
|
|
JP7612571B2
(ja)
|
2018-10-03 |
2025-01-14 |
ゼンコア インコーポレイテッド |
Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
|
|
US20210395392A1
(en)
|
2018-10-09 |
2021-12-23 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
TWI855000B
(zh)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Ｓｔｉｎｇ促效化合物
|
|
KR20210075147A
(ko)
|
2018-10-12 |
2021-06-22 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
제제의 전달을 위한 소형 중합체 담체
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
WO2020079581A1
(en)
|
2018-10-16 |
2020-04-23 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
WO2020081493A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
US12152019B2
(en)
|
2018-10-17 |
2024-11-26 |
Merck Sharp & Dohme Llc |
Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3867269A1
(en)
|
2018-10-18 |
2021-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3866850B1
(en)
|
2018-10-19 |
2024-07-24 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
US20210324081A1
(en)
|
2018-10-22 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
CN112912403A
(zh)
|
2018-10-23 |
2021-06-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
KR20210080460A
(ko)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
이종이량체성 Fc-융합된 단백질
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
US11564995B2
(en)
|
2018-10-29 |
2023-01-31 |
Wisconsin Alumni Research Foundation |
Peptide-nanoparticle conjugates
|
|
KR20210084552A
(ko)
|
2018-10-29 |
2021-07-07 |
위스콘신 얼럼나이 리서어치 화운데이션 |
향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머
|
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
TW202021981A
(zh)
|
2018-11-01 |
2020-06-16 |
美商奇諾治療有限公司 |
G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
EP3873464B1
(en)
|
2018-11-01 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
AU2019375416A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive T-cells
|
|
JP2022506586A
(ja)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
|
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020094744A1
(en)
|
2018-11-06 |
2020-05-14 |
Genmab A/S |
Antibody formulation
|
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
EP3890773A4
(en)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
MODULATION OF DENDRITIC CELL LINES
|
|
JP2022512973A
(ja)
|
2018-11-09 |
2022-02-07 |
ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー |
腫瘍微小環境の組成を測定するための方法及び組成物
|
|
CN113166269B
(zh)
|
2018-11-13 |
2025-01-07 |
指南针制药有限责任公司 |
对抗检查点分子的多特异性结合构建体及其用途
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
SG11202105078XA
(en)
|
2018-11-14 |
2021-06-29 |
Bayer Ag |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
|
WO2020102375A1
(en)
|
2018-11-14 |
2020-05-22 |
Regeneron Pharmaceuticals, Inc. |
Intralesional administration of pd-1 inhibitors for treating skin cancer
|
|
CA3119742A1
(en)
|
2018-11-16 |
2020-05-22 |
Arqule, Inc. |
Pharmaceutical combination for treatment of cancer
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
TWI828800B
(zh)
|
2018-11-16 |
2024-01-11 |
美商阿克思生物科學有限公司 |
Arg1及/或arg2之抑制劑
|
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
|
US12466831B2
(en)
|
2018-11-20 |
2025-11-11 |
Merck Sharp & Dohme Llc |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
US12414952B2
(en)
|
2018-11-20 |
2025-09-16 |
Merck Sharp & Dohme Llc |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
EP3883964A1
(en)
|
2018-11-20 |
2021-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
EP3886842A1
(en)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Combination treatment of hiv infections
|
|
TWI818120B
(zh)
|
2018-11-27 |
2023-10-11 |
日商小野藥品工業股份有限公司 |
藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
|
|
EP3887823B1
(en)
|
2018-11-28 |
2024-01-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kit for assaying lytic potential of immune effector cells
|
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
WO2020112581A1
(en)
|
2018-11-28 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
JP7406556B2
(ja)
|
2018-11-30 |
2023-12-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Ｈｉｖ療法に有用な化合物
|
|
EP3886988A1
(en)
|
2018-11-30 |
2021-10-06 |
Merck Sharp & Dohme Corp. |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
KR20250167680A
(ko)
|
2018-11-30 |
2025-12-01 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
FI3886914T3
(fi)
|
2018-11-30 |
2023-05-26 |
Bristol Myers Squibb Co |
Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä
|
|
EP3886875B1
(en)
|
2018-11-30 |
2024-05-08 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
EP3890749B1
(en)
|
2018-12-04 |
2025-10-29 |
Sumitomo Pharma America, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
KR102835299B1
(ko)
|
2018-12-04 |
2025-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|
|
MX2021006578A
(es)
|
2018-12-05 |
2021-07-07 |
Genentech Inc |
Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
|
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
MA54448A
(fr)
|
2018-12-11 |
2021-10-20 |
Theravance Biopharma R&D Ip Llc |
Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
|
|
KR20210102334A
(ko)
|
2018-12-12 |
2021-08-19 |
브리스톨-마이어스 스큅 컴퍼니 |
트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
WO2020123011A1
(en)
|
2018-12-13 |
2020-06-18 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
EP3897622A4
(en)
|
2018-12-18 |
2022-09-28 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
KR20210104704A
(ko)
|
2018-12-19 |
2021-08-25 |
바이엘 악티엔게젤샤프트 |
항 ceacam6 및 tim3 항체의 제약 조합물
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
BR112021011874A2
(pt)
|
2018-12-20 |
2021-09-08 |
Novartis Ag |
Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
JOP20210159A1
(ar)
|
2018-12-21 |
2023-01-30 |
Novartis Ag |
أجسام مضادة لـ pmel17 ومترافقات منها
|
|
CA3119584A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
CA3119582A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1.beta. binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
US20220054524A1
(en)
|
2018-12-21 |
2022-02-24 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
AU2019413690A1
(en)
*
|
2018-12-27 |
2021-08-12 |
Gigagen, Inc. |
Anti-PD-L1 binding proteins and methods of use thereof
|
|
WO2020140012A1
(en)
|
2018-12-27 |
2020-07-02 |
Amgen Inc. |
Lyophilized virus formulations
|
|
BR112021013157A8
(pt)
|
2019-01-03 |
2022-12-06 |
Inst Nat Sante Rech Med |
Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t
|
|
EA202191903A1
(ru)
|
2019-01-09 |
2021-11-12 |
Селджин Корпорейшн |
Антипролиферативные соединения и вторые активные агенты для комбинированного применения
|
|
CN114409630B
(zh)
|
2019-01-09 |
2024-04-02 |
细胞基因公司 |
包含氧代异吲哚化合物的药物组合物以及使用它的方法
|
|
AU2020206694B2
(en)
|
2019-01-09 |
2025-05-22 |
Celgene Corporation |
Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
|
|
EP3911642A1
(en)
|
2019-01-14 |
2021-11-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
US12391675B2
(en)
|
2019-01-14 |
2025-08-19 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
EP3911417B1
(en)
|
2019-01-14 |
2022-10-26 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators , for use in the treatment of cancer
|
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
|
WO2020150113A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
|
ES3011707T3
(en)
|
2019-01-15 |
2025-04-08 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
US11116729B2
(en)
|
2019-01-17 |
2021-09-14 |
Georgia Tech Research Corporation |
Drug delivery systems containing oxidized cholesterols
|
|
WO2020151572A1
(en)
|
2019-01-23 |
2020-07-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-l1 diabodies and the use thereof
|
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
MA54863A
(fr)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
|
|
JP7442536B2
(ja)
|
2019-01-30 |
2024-03-04 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物
|
|
EP3917964A1
(en)
|
2019-02-01 |
2021-12-08 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
|
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
AU2020221247B2
(en)
|
2019-02-12 |
2024-12-12 |
Sumitomo Pharma America, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020165370A1
(en)
|
2019-02-13 |
2020-08-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
WO2020165833A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
MA54947A
(fr)
|
2019-02-15 |
2021-12-22 |
Incyte Corp |
Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
SG11202108955QA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to nkp30 and uses thereof
|
|
SG11202109085YA
(en)
*
|
2019-02-21 |
2021-09-29 |
Eucure Beijing Biopharma Co Ltd |
Anti-pd-l1 antibody and use thereof
|
|
JP7492526B2
(ja)
|
2019-02-27 |
2024-05-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍａｌａｔ１発現のモジュレーター
|
|
AU2020228296B2
(en)
|
2019-02-28 |
2025-10-02 |
Regeneron Pharmaceuticals, Inc. |
Administration of PD-1 inhibitors for treating skin cancer
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
BR112021017551A2
(pt)
|
2019-03-05 |
2021-11-09 |
Amgen Inc |
Uso de vírus oncolíticos para o tratamento de câncer
|
|
CN113677707A
(zh)
|
2019-03-06 |
2021-11-19 |
瑞泽恩制药公司 |
用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020185859A1
(en)
|
2019-03-12 |
2020-09-17 |
Arcus Biosciences, Inc. |
Treatment of oncogene-driven cancers
|
|
JP7730761B2
(ja)
|
2019-03-14 |
2025-08-28 |
ジェネンテック， インコーポレイテッド |
抗ＨＥＲ２ ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置
|
|
CN113795264A
(zh)
|
2019-03-19 |
2021-12-14 |
瓦尔希伯伦私人肿瘤研究基金会 |
采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP2022527192A
(ja)
|
2019-03-29 |
2022-05-31 |
ジェネンテック， インコーポレイテッド |
細胞表面タンパク質相互作用のモジュレーター並びにそれに関する方法及び組成物
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
EP3947463A4
(en)
|
2019-03-29 |
2022-12-21 |
Arcus Biosciences, Inc. |
CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
CN109929037B
(zh)
*
|
2019-04-01 |
2023-03-17 |
华博生物医药技术（上海）有限公司 |
针对程序性死亡配体的结合物及其应用
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3946462A1
(en)
|
2019-04-02 |
2022-02-09 |
BicycleTX Limited |
Bicycle toxin conjugates and uses thereof
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
CA3135802A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
BR112021020225A2
(pt)
|
2019-04-12 |
2021-12-07 |
Vascular Biogenics Ltd |
Métodos de terapia antitumoral
|
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
JP7725066B2
(ja)
*
|
2019-04-18 |
2025-08-19 |
キューエルエスエフ バイオセラピューティック インコーポレイテッド |
ヒト化抗ｐｄ－ｌ１抗体
|
|
EP3956364A1
(en)
|
2019-04-19 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Anti-mertk antibodies and their methods of use
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
CN113784981B
(zh)
|
2019-04-23 |
2025-01-28 |
先天制药公司 |
Cd73阻断抗体
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
EP3963109A1
(en)
|
2019-04-30 |
2022-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US20200345820A1
(en)
|
2019-05-01 |
2020-11-05 |
Sensei Biotherapeutics, Inc. |
Combination therapies for cancer
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
|
EP3965816A1
(en)
|
2019-05-06 |
2022-03-16 |
MedImmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
|
IL287801A
(en)
|
2019-05-07 |
2022-07-01 |
Immunicom Inc |
Increasing responses to checkpoint inhibitors by extracorporeal apheresis
|
|
EP3969438A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
WO2020236253A1
(en)
|
2019-05-20 |
2020-11-26 |
Massachusetts Institute Of Technology |
Boronic ester prodrugs and uses thereof
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
CN114206926B
(zh)
|
2019-06-10 |
2022-06-17 |
山东博安生物技术股份有限公司 |
抗PDL1和TGFβ的双功能融合蛋白及其用途
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
WO2020248156A1
(zh)
*
|
2019-06-12 |
2020-12-17 |
苏州工业园区唯可达生物科技有限公司 |
Pd-l1靶向结合剂及其用途
|
|
CN114206379A
(zh)
|
2019-06-18 |
2022-03-18 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
|
|
WO2020255011A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
CN114040777A
(zh)
|
2019-06-25 |
2022-02-11 |
信达生物制药(苏州)有限公司 |
包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
AU2020308053A1
(en)
|
2019-06-26 |
2022-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
IL1RAP binding proteins
|
|
WO2020260547A1
(en)
|
2019-06-27 |
2020-12-30 |
Rigontec Gmbh |
Design method for optimized rig-i ligands
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
KR20220028075A
(ko)
|
2019-07-03 |
2022-03-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20220356255A1
(en)
*
|
2019-07-15 |
2022-11-10 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
|
|
MX2022001434A
(es)
|
2019-08-05 |
2022-02-22 |
Ono Pharmaceutical Co |
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
|
PH12022550361A1
(en)
|
2019-08-14 |
2023-02-27 |
Incyte Corp |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
MX2022001719A
(es)
|
2019-08-15 |
2022-03-11 |
Silverback Therapeutics Inc |
Formulaciones de conjugados de benzazepina y usos de las mismas.
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
EP4017882A4
(en)
*
|
2019-08-23 |
2023-09-27 |
Wuxi Biologics Ireland Limited |
Humanized antibodies against pd-l1
|
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
WO2021037007A1
(zh)
|
2019-08-29 |
2021-03-04 |
荣昌生物制药(烟台)股份有限公司 |
抗pd-l1抗体及其应用
|
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
JP2022547719A
(ja)
|
2019-09-13 |
2022-11-15 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニストおよびその使用
|
|
US20240377413A1
(en)
|
2019-09-16 |
2024-11-14 |
Bristol-Myers Squibb Company |
Dual capture method for analysis of antibody-drug conjugates
|
|
US11655303B2
(en)
|
2019-09-16 |
2023-05-23 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
|
AU2020349519A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
US20220411388A1
(en)
|
2019-09-17 |
2022-12-29 |
Bial - R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
JP2022549227A
(ja)
|
2019-09-17 |
2022-11-24 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
|
|
US20220348632A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof
|
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
|
CN114786776A
(zh)
|
2019-09-18 |
2022-07-22 |
拉姆卡普生物阿尔法股份公司 |
针对ceacam5和cd3的双特异性抗体
|
|
KR20220081977A
(ko)
|
2019-09-18 |
2022-06-16 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 스캐폴드를 포함하는 pd-l1 결합분자(pd-l1 binding molecules comprising shiga toxin a subunit scaffolds)
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
KR20220068242A
(ko)
|
2019-09-20 |
2022-05-25 |
트랜스진 |
Hpv 폴리펩티드 및 il-2를 암호화하는 폭스바이러스와 항-pd-l1 항체의 조합
|
|
JP2022549273A
(ja)
|
2019-09-22 |
2022-11-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
|
|
TW202521984A
(zh)
|
2019-09-25 |
2025-06-01 |
美商表面腫瘤學有限責任公司 |
抗ｉｌ－２７抗體及其用途
|
|
JP7739269B2
(ja)
|
2019-09-25 |
2025-09-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
がん療法のための複合バイオマーカー
|
|
TWI867053B
(zh)
|
2019-09-26 |
2024-12-21 |
瑞士商諾華公司 |
抗病毒吡唑并吡啶酮化合物
|
|
EP4034565A4
(en)
*
|
2019-09-26 |
2023-09-27 |
Orionis Biosciences, Inc. |
PD-L1 TARGETED CHIMERIC PROTEINS AND THEIR USES
|
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
|
WO2021058711A2
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
US20220356221A1
(en)
|
2019-09-28 |
2022-11-10 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022005826A2
(pt)
|
2019-09-30 |
2022-06-21 |
Incyte Corp |
Compostos de pirido[3,2-d]pirimidina como imunomoduladores
|
|
WO2021064567A1
(en)
|
2019-09-30 |
2021-04-08 |
Astrazeneca Ab |
Combination treatment for cancer
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
AU2020358979A1
(en)
|
2019-10-03 |
2022-04-21 |
Xencor, Inc. |
Targeted IL-12 heterodimeric Fc-fusion proteins
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
MX2022003517A
(es)
*
|
2019-10-04 |
2022-04-25 |
Seagen Inc |
Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
MX2022004390A
(es)
|
2019-10-11 |
2022-08-08 |
Incyte Corp |
Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
|
|
EP4045061A4
(en)
|
2019-10-14 |
2024-04-17 |
ARO Biotherapeutics Company |
FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021074683A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
Bispecific anti-pd-l1 and anti-fcrn polypeptides
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157889A1
(en)
|
2019-10-17 |
2021-04-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Ｔｉｍ－３阻害剤およびその使用
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
EP4048795A1
(en)
|
2019-10-23 |
2022-08-31 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
BR112022008074A2
(pt)
|
2019-10-28 |
2022-07-12 |
Shanghai Inst Materia Medica Cas |
Composto de ácido oxocarboxílico heterocíclico de cinco membros e uso médico do mesmo
|
|
US20240122938A1
(en)
|
2019-10-29 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating uveal melanoma
|
|
BR112022007971A8
(pt)
|
2019-10-29 |
2023-02-07 |
Eisai R&D Man Co Ltd |
Combinação de antagonista do pd-1, inibidor da tirosina quinase vegfr/fgfr/ret e inibidor da cbp/beta-catenina para o tratamento do câncer
|
|
KR20220092918A
(ko)
|
2019-11-04 |
2022-07-04 |
알렉터 엘엘씨 |
Siglec-9 ecd 융합 분자 및 이의 사용 방법
|
|
JP2023500506A
(ja)
|
2019-11-04 |
2023-01-06 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための組み合わせ療法
|
|
JP2022554346A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレーション |
２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
JP2022553803A
(ja)
|
2019-11-06 |
2022-12-26 |
ジェネンテック， インコーポレイテッド |
血液がんの処置のための診断方法及び治療方法
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4055609A1
(en)
|
2019-11-07 |
2022-09-14 |
Oncxerna Therapeutics, Inc. |
Classification of tumor microenvironments
|
|
CN115942973A
(zh)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
用于黑色素瘤的lag-3拮抗剂疗法
|
|
BR112022009031A2
(pt)
|
2019-11-11 |
2022-10-11 |
Incyte Corp |
Sais e formas cristalinas de um inibidor de pd-1/pd-l1
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
MX2022005839A
(es)
|
2019-11-19 |
2022-06-09 |
Bristol Myers Squibb Co |
Compuestos utiles como inhibidores de la proteina helios.
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
CA3160307A1
(en)
|
2019-11-22 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
CN115151306A
(zh)
|
2019-11-26 |
2022-10-04 |
百时美施贵宝公司 |
(r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
|
|
WO2021108025A1
(en)
|
2019-11-26 |
2021-06-03 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
PL4065582T3
(pl)
|
2019-11-26 |
2025-08-18 |
Ikena Oncology, Inc. |
Polimorficzne pochodne karbazolu i ich zastosowania
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
|
|
AU2020402097A1
(en)
|
2019-12-13 |
2022-07-07 |
Cugene Inc. |
Novel interleukin-15 (IL-15) fusion proteins and uses thereof
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
WO2021126725A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021119753A1
(en)
|
2019-12-18 |
2021-06-24 |
Ctxt Pty Limited |
Compounds
|
|
US20230089255A1
(en)
|
2019-12-19 |
2023-03-23 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
WO2021123243A1
(en)
|
2019-12-19 |
2021-06-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
|
EP4081513B1
(en)
|
2019-12-23 |
2024-11-20 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
AU2020412780A1
(en)
|
2019-12-23 |
2022-07-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
KR20220120624A
(ko)
|
2019-12-23 |
2022-08-30 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 피페라진 유도체
|
|
IL294273A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds are useful as t-cell activators
|
|
AU2020415377A1
(en)
|
2019-12-23 |
2022-08-18 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as T cell activators
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
EP4085060A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
CN114929728A
(zh)
|
2020-01-06 |
2022-08-19 |
百时美施贵宝公司 |
免疫调节剂
|
|
US20230054718A1
(en)
|
2020-01-07 |
2023-02-23 |
Hifibio (Hk) Limited |
Anti-galectin-9 antibody and uses thereof
|
|
WO2021141751A1
(en)
|
2020-01-07 |
2021-07-15 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
JP7573622B2
(ja)
|
2020-01-10 |
2024-10-25 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
CN115279771B
(zh)
|
2020-01-15 |
2025-03-21 |
缆图药品公司 |
Map4k1抑制剂
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021155042A1
(en)
|
2020-01-28 |
2021-08-05 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
|
|
WO2021152495A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP4097130A1
(en)
|
2020-01-30 |
2022-12-07 |
Ona Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
|
EP4097126A1
(en)
|
2020-01-30 |
2022-12-07 |
Gnubiotics Sciences SA |
Compositions comprising pig stomach mucins and uses thereof
|
|
CN115397459A
(zh)
|
2020-01-31 |
2022-11-25 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
|
US20230072528A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
JP2023513553A
(ja)
|
2020-02-07 |
2023-03-31 |
エイアイ・セラピューティクス・インコーポレーテッド |
抗ウイルス性組成物および使用の方法
|
|
WO2021167964A1
(en)
|
2020-02-18 |
2021-08-26 |
Alector Llc |
Pilra antibodies and methods of use thereof
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
JP2023516195A
(ja)
|
2020-02-26 |
2023-04-18 |
バイオグラフ ５５，インク． |
Ｃ１９ ｃ３８二特異性抗体
|
|
WO2021174045A1
(en)
|
2020-02-28 |
2021-09-02 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
|
EP4110955A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
|
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
US20230089536A1
(en)
|
2020-03-06 |
2023-03-23 |
Celgene Quanticel Research, Inc. |
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
|
|
EP4114450A1
(en)
|
2020-03-06 |
2023-01-11 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Modulating anti-tumor immunity
|
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
|
MX2022011050A
(es)
|
2020-03-06 |
2022-12-15 |
Ona Therapeutics S L |
Anticuerpos anti-cd36 y su uso para tratar cancer.
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
IL295569A
(en)
|
2020-03-19 |
2022-10-01 |
Arcus Biosciences Inc |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
KR20220157446A
(ko)
|
2020-03-23 |
2022-11-29 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-ccr8 항체
|
|
WO2021202501A1
(en)
|
2020-03-30 |
2021-10-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2021203131A1
(en)
|
2020-03-31 |
2021-10-07 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021206158A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
がん治療方法
|
|
WO2021207689A2
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
STING AGONISTIC COMPOUND
|
|
CA3175490A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Limited |
Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
|
|
EP4135844A1
(en)
|
2020-04-16 |
2023-02-22 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
|
WO2021216572A1
(en)
|
2020-04-20 |
2021-10-28 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
EP4139341A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
|
KR20230037069A
(ko)
|
2020-04-22 |
2023-03-15 |
이오반스 바이오테라퓨틱스, 인크. |
환자-특이적 면역요법을 위해 세포의 제조를 조정하기 위한 시스템 및 방법
|
|
AU2021260960A1
(en)
|
2020-04-22 |
2022-11-24 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CN115835909A
(zh)
|
2020-05-05 |
2023-03-21 |
泰昂治疗公司 |
大麻素受体2型（cb2）调节剂和其用途
|
|
WO2021224215A1
(en)
|
2020-05-05 |
2021-11-11 |
F. Hoffmann-La Roche Ag |
Predicting response to pd-1 axis inhibitors
|
|
PE20230680A1
(es)
|
2020-05-06 |
2023-04-21 |
Merck Sharp And Dohme Llc |
Inhibidores de il4i1 y metodos de uso
|
|
US12202882B2
(en)
|
2020-05-08 |
2025-01-21 |
Alpine Immune Sciences, Inc. |
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
|
|
JP2023526282A
(ja)
|
2020-05-13 |
2023-06-21 |
ボナム セラピューティクス，インク． |
タンパク質複合体の組成物及びその使用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
EP4149424A1
(en)
|
2020-05-13 |
2023-03-22 |
Massachusetts Institute Of Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
AU2021280245A1
(en)
|
2020-05-26 |
2022-12-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cervical cancer by administering a PD-1 inhibitor
|
|
EP4157343A2
(en)
|
2020-05-26 |
2023-04-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
|
EP4157319A1
(en)
|
2020-05-28 |
2023-04-05 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
WO2021242794A2
(en)
|
2020-05-29 |
2021-12-02 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
KR20230019152A
(ko)
|
2020-06-02 |
2023-02-07 |
아르커스 바이오사이언시즈 인코포레이티드 |
Tigit에 대한 항체
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
|
TW202214623A
(zh)
|
2020-06-10 |
2022-04-16 |
美商施萬生物製藥研發 Ip有限責任公司 |
結晶型alk5抑制劑及其用途
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
CN111925434B
(zh)
*
|
2020-06-22 |
2023-06-27 |
南昌大学 |
一种单克隆抗体的筛选方法
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2021262969A1
(en)
|
2020-06-24 |
2021-12-30 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
AU2021296876A1
(en)
|
2020-06-25 |
2023-02-02 |
Celgene Corporation |
Methods for treating cancer with combination therapies
|
|
AU2021296917A1
(en)
|
2020-06-26 |
2023-02-02 |
Amgen Inc. |
IL-10 muteins and fusion proteins thereof
|
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
|
US20230250173A1
(en)
|
2020-07-01 |
2023-08-10 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
|
AU2021300362A1
(en)
|
2020-07-01 |
2023-02-23 |
ARS Pharmaceuticals, Inc. |
Anti-ASGR1 antibody conjugates and uses thereof
|
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
|
KR20230035598A
(ko)
|
2020-07-07 |
2023-03-14 |
셀진 코포레이션 |
(s)-4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴을 포함하는 약제학적 조성물 및 이를 사용하는 방법
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022023379A1
(en)
|
2020-07-28 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for preventing and treating a cancer
|
|
TW202221031A
(zh)
|
2020-07-30 |
2022-06-01 |
英商阿法克塔生命科學有限公司 |
血清半衰期延長之pd-l1抑制多肽
|
|
MX2023001217A
(es)
|
2020-07-30 |
2023-03-03 |
Kymera Therapeutics Inc |
Metodos de tratamiento de linfomas mutantes.
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20250028534A
(ko)
|
2020-08-05 |
2025-02-28 |
신테카인, 인크. |
Il10 수용체 결합 분자 및 사용 방법
|
|
US20230272094A1
(en)
|
2020-08-05 |
2023-08-31 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
|
CA3190459A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Gp130 binding molecules and methods of use
|
|
JP7767391B2
(ja)
|
2020-08-05 |
2025-11-11 |
シンセカイン インコーポレイテッド |
ＩＬ１０Ｒａ結合分子および使用方法
|
|
WO2022032005A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10rb binding molecules and methods of use
|
|
MX2023001707A
(es)
|
2020-08-10 |
2023-05-04 |
Shanghai Xunbaihui Biotechnology Co Ltd |
Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
|
MA71214A
(fr)
|
2020-08-26 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
|
|
WO2022047046A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
BR112023003553A2
(pt)
|
2020-08-31 |
2023-04-04 |
Bristol Myers Squibb Co |
Assinatura de localização celular e imunoterapia
|
|
JP2023540490A
(ja)
|
2020-09-02 |
2023-09-25 |
ファーマブシン インコーポレイテッド |
がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
|
|
KR20230061499A
(ko)
|
2020-09-03 |
2023-05-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 저해제 투여에 의한 암 통증 치료 방법
|
|
CN114316045B
(zh)
*
|
2020-09-29 |
2024-07-12 |
英诺欧奇生物医药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
AU2021351500A1
(en)
*
|
2020-09-30 |
2023-06-08 |
Adept Biopharmaceutical And Technology Ltd. |
ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES
|
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
|
|
JP2023548051A
(ja)
|
2020-10-23 |
2023-11-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
肺がんのためのｌａｇ－３アンタゴニスト療法
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
JP2023549678A
(ja)
|
2020-10-28 |
2023-11-29 |
イケナ オンコロジー， インコーポレイテッド |
ＡＨＲ阻害剤のＰＤｘ阻害剤またはドキソルビシンとの組み合わせ
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
MX2023005362A
(es)
|
2020-11-06 |
2023-06-22 |
Incyte Corp |
Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
|
|
KR20230104659A
(ko)
|
2020-11-08 |
2023-07-10 |
씨젠 인크. |
면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
EP4245301A4
(en)
|
2020-11-13 |
2024-08-21 |
ONO Pharmaceutical Co., Ltd. |
TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
|
|
WO2022103904A1
(en)
|
2020-11-13 |
2022-05-19 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
|
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
IL302836A
(en)
|
2020-11-17 |
2023-07-01 |
Seagen Inc |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
KR20230117162A9
(ko)
|
2020-12-02 |
2024-03-21 |
제넨테크, 인크. |
신보조 및 보조 요로상피 암종 요법을 위한 방법 및 조성물
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
WO2022125497A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
WO2022121846A1
(zh)
*
|
2020-12-08 |
2022-06-16 |
博际生物医药科技(杭州)有限公司 |
Pd-l1抗体及其应用
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
JP2024501207A
(ja)
|
2020-12-16 |
2024-01-11 |
ゴッサマー バイオ サービシズ、インコーポレイテッド |
Ｔ細胞活性化剤として有用な化合物
|
|
EP4262858A1
(en)
|
2020-12-16 |
2023-10-25 |
Molecular Templates, Inc. |
Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
|
|
HRP20240213T1
(hr)
|
2020-12-18 |
2024-04-26 |
Lamkap Bio Beta Ag |
Bispecifična antitijela protiv ceacam5 i cd47
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
EP4566674A3
(en)
|
2020-12-28 |
2025-08-06 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
AU2021411952A1
(en)
|
2020-12-29 |
2023-08-10 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
|
JP2024503300A
(ja)
|
2020-12-30 |
2024-01-25 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
TW202241954A
(zh)
|
2021-01-04 |
2022-11-01 |
美商梅爾莎納醫療公司 |
靶向ｂ７－ｈ４之抗體－藥物共軛體和使用彼之方法
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
EP4274616A2
(en)
|
2021-01-11 |
2023-11-15 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
|
WO2022155541A1
(en)
|
2021-01-14 |
2022-07-21 |
AskGene Pharma, Inc. |
Interferon prodrugs and methods of making and using the same
|
|
EP4282413A4
(en)
|
2021-01-21 |
2024-12-25 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
COMPOSITION AND METHOD FOR TREATING TUMORS
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
US20240423972A1
(en)
|
2021-02-01 |
2024-12-26 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
JP2024506844A
(ja)
|
2021-02-03 |
2024-02-15 |
ジェネンテック， インコーポレイテッド |
Ｃｂｌ－ｂ阻害剤としてのアミド
|
|
AR124800A1
(es)
|
2021-02-03 |
2023-05-03 |
Genentech Inc |
Lactamas como inhibidores cbl-b
|
|
US20240139198A1
(en)
|
2021-02-10 |
2024-05-02 |
Curon Biopharmaceutical (Shanghai) Co., Limited |
Method and combination for treating tumors
|
|
IL305101A
(en)
*
|
2021-02-10 |
2023-10-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
ANTI-PD-L1 antibody and its use
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CA3210553A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
AU2022230795B2
(en)
|
2021-03-02 |
2025-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN117677634A
(zh)
|
2021-03-05 |
2024-03-08 |
利达提斯有限公司 |
三聚体多肽及其在治疗癌症中的用途
|
|
WO2022192145A1
(en)
|
2021-03-08 |
2022-09-15 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
CN115073599B
(zh)
*
|
2021-03-16 |
2023-04-28 |
北京天广实生物技术股份有限公司 |
结合pd-l1的抗体及其用途
|
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
CN117355298A
(zh)
|
2021-03-19 |
2024-01-05 |
生物治疗探索股份有限公司 |
用于调节训练免疫的化合物及其使用方法
|
|
EP4313123A1
(en)
|
2021-03-23 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
AU2022245322A1
(en)
|
2021-03-25 |
2023-10-05 |
Oncxerna Therapeutics, Inc. |
Targeted therapies in cancer
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
MX2023011310A
(es)
|
2021-03-26 |
2023-10-05 |
Innate Pharma |
Anclajes de citocina para proteinas de celulas nk de union a nkp46.
|
|
US12071442B2
(en)
|
2021-03-29 |
2024-08-27 |
Nimbus Saturn, Inc. |
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
|
|
AU2022246593A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4314060A1
(en)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
BR112023020410A2
(pt)
|
2021-04-05 |
2023-11-28 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer
|
|
WO2022216644A1
(en)
|
2021-04-06 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022254104A1
(en)
|
2021-04-08 |
2023-10-26 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
|
EP4320147A4
(en)
|
2021-04-08 |
2025-06-18 |
Marengo Therapeutics, Inc. |
TCR-BINDING MULTIFUNCTIONAL MOLECULES AND USES THEREOF
|
|
JP2024513246A
(ja)
|
2021-04-09 |
2024-03-22 |
ジェネンテック， インコーポレイテッド |
Ｒａｆ阻害剤及びｐｄ－１軸阻害剤を用いた併用治療
|
|
CA3214952A1
(en)
|
2021-04-09 |
2022-10-13 |
Silvana Marcel LEIT DE MORADEI |
Cbl-b modulators and uses thereof
|
|
JP2024515263A
(ja)
|
2021-04-09 |
2024-04-08 |
オーエスイー・イミュノセラピューティクス |
改善された特性を有する二機能性分子のための新規足場構造
|
|
JP2024513505A
(ja)
|
2021-04-09 |
2024-03-25 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
腫瘍を治療するための組成物及び方法
|
|
EP4320160A1
(en)
|
2021-04-09 |
2024-02-14 |
Seagen Inc. |
Methods of treating cancer with anti-tigit antibodies
|
|
US20240182572A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
US20240228659A1
(en)
|
2021-04-14 |
2024-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
JP2024517610A
(ja)
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
|
|
EP4323008A1
(en)
|
2021-04-14 |
2024-02-21 |
ARO Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
CN113150153B
(zh)
*
|
2021-04-15 |
2022-05-10 |
博奥信生物技术（南京）有限公司 |
一种抗人pdl1单克隆抗体及其用途
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
MX2023012277A
(es)
|
2021-04-16 |
2023-12-07 |
Novartis Ag |
Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
|
|
CN117597150A
(zh)
|
2021-04-20 |
2024-02-23 |
思进公司 |
抗体依赖性细胞毒性的调节
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
WO2022236058A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
|
CA3218578A1
(en)
|
2021-05-14 |
2022-11-17 |
Carol Elaine O'hear |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
CN117396222A
(zh)
|
2021-05-21 |
2024-01-12 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
WO2022246177A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl compounds
|
|
JP2024521712A
(ja)
|
2021-05-21 |
2024-06-04 |
アーカス バイオサイエンシーズ，インコーポレーテッド |
Ａｘｌ阻害化合物
|
|
CA3218786A1
(en)
|
2021-05-25 |
2022-12-01 |
Lifei HOU |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
CA3220191A1
(en)
|
2021-05-26 |
2022-12-01 |
Tania Crombet Ramos |
Use of therapeutic compositions for the treatment of patients with tumours of epithelial origin
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
CN113234152B
(zh)
*
|
2021-06-03 |
2023-05-02 |
天津科技大学 |
程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用
|
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
|
CA3218692A1
(en)
|
2021-06-04 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Anti-sirp-alpha antibodies
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
|
BR112023025331A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
AU2022289317A1
(en)
|
2021-06-10 |
2023-12-14 |
Ono Pharmaceutical Co., Ltd. |
Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy
|
|
US20230034659A1
(en)
*
|
2021-06-17 |
2023-02-02 |
Sparx Bioscience Limited |
Anti-pdl1 antibodies and uses thereof
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
US20240316005A1
(en)
|
2021-07-05 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
US12441727B2
(en)
|
2021-07-07 |
2025-10-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
AR126442A1
(es)
|
2021-07-14 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
|
EP4370139A4
(en)
|
2021-07-14 |
2025-10-15 |
Synthekine Inc |
METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
|
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
|
AR126453A1
(es)
|
2021-07-15 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
|
EP4373505A1
(en)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
|
KR20240046926A
(ko)
*
|
2021-07-23 |
2024-04-11 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
Sars-cov-2, 그 변이체 및 관련 코로나바이러스를 강력하고 광범위하게 중화하는 단일클론항체의 특성 분석 및 사용 방법
|
|
WO2023010094A2
(en)
|
2021-07-28 |
2023-02-02 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
|
US20250009877A1
(en)
|
2021-07-30 |
2025-01-09 |
Seagen Inc. |
Treatment for cancer
|
|
US20250206836A1
(en)
|
2021-07-30 |
2025-06-26 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
EP4380596A1
(en)
|
2021-08-04 |
2024-06-12 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
IL310773A
(en)
|
2021-09-02 |
2024-04-01 |
Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts |
Anti-CECAM6 antibodies with reduced side effects
|
|
TW202325306A
(zh)
|
2021-09-02 |
2023-07-01 |
美商天恩治療有限公司 |
改良免疫細胞之生長及功能的方法
|
|
EP4399206A1
(en)
|
2021-09-08 |
2024-07-17 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
PE20242113A1
(es)
|
2021-10-14 |
2024-10-28 |
Incyte Corp |
Compuestos de quinolina como inhibidores de kras
|
|
CA3234552A1
(en)
|
2021-10-20 |
2023-04-27 |
Synthekine, Inc. |
Heterodimeric fc cytokines and uses thereof
|
|
JP2024539164A
(ja)
|
2021-10-21 |
2024-10-28 |
杭州阿諾生物医薬科技有限公司 |
融合ポリペプチドの一種とその使用
|
|
EP4423249A1
(en)
|
2021-10-28 |
2024-09-04 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
CN116072211A
(zh)
*
|
2021-10-29 |
2023-05-05 |
京东方科技集团股份有限公司 |
抗体互补决定簇序列比对的方法及其装置和电子设备
|
|
KR20240099362A
(ko)
|
2021-10-29 |
2024-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
혈액암에 대한 lag-3 길항제 요법
|
|
AU2022378630A1
(en)
|
2021-10-29 |
2024-05-09 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
CA3237437A1
(en)
|
2021-11-09 |
2023-05-19 |
Robert Pierce |
Anti-vista antibodies and uses thereof
|
|
EP4433504A1
(en)
|
2021-11-17 |
2024-09-25 |
Institut National de la Santé et de la Recherche Médicale |
Universal sarbecovirus vaccines
|
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
WO2023097211A1
(en)
|
2021-11-24 |
2023-06-01 |
The University Of Southern California |
Methods for enhancing immune checkpoint inhibitor therapy
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ｃｋ１２抑制劑
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
US20250041261A1
(en)
|
2021-12-21 |
2025-02-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023122134A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
WO2023129438A1
(en)
|
2021-12-28 |
2023-07-06 |
Wisconsin Alumni Research Foundation |
Hydrogel compositions for use for depletion of tumor associated macrophages
|
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
|
JP2025503962A
(ja)
|
2022-01-26 |
2025-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞がんのための併用療法
|
|
KR20240144944A
(ko)
|
2022-01-28 |
2024-10-04 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
항종양제와 관련된 질병 또는 증상을 예방하거나 치료하는 방법
|
|
IL314524A
(en)
|
2022-01-28 |
2024-09-01 |
Georgiamune Inc |
Antibodies to programmed cell death protein 1 that are agonists for PD-1
|
|
KR20240137084A
(ko)
|
2022-01-31 |
2024-09-19 |
센테사 파마슈티칼스 (유케이) 리미티드 |
활성화가능한 이중특이적 항-cd47 및 항-pd-l1 단백질 및 그의 용도
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
EP4479388A1
(en)
|
2022-02-14 |
2024-12-25 |
Gilead Sciences, Inc. |
Antiviral naphthyridinone compounds
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
US12052261B2
(en)
|
2022-02-15 |
2024-07-30 |
Bank Of America Corporation |
System and method for authenticating the receiving end of data transmission via LiFi and holochain network
|
|
US12074641B2
(en)
|
2022-02-15 |
2024-08-27 |
Bank Of America Corporation |
System and method for secured data transmission using LiFi and holochain network
|
|
JP2025506696A
(ja)
|
2022-02-17 |
2025-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを処置するためのチェックポイント阻害剤と腫瘍溶解性ウイルスの組合せ
|
|
KR20240150493A
(ko)
|
2022-02-21 |
2024-10-15 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
화합물 및 그 용도
|
|
EP4482947A1
(en)
|
2022-02-24 |
2025-01-01 |
Amazentis SA |
Uses of urolithins
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
MX2024010773A
(es)
|
2022-03-03 |
2024-09-10 |
Pfizer |
Anticuerpos multiespecificos y usos de estos.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
AU2023232823A1
(en)
|
2022-03-07 |
2024-09-12 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
|
AU2023230110A1
(en)
|
2022-03-08 |
2024-10-24 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
AU2023246985A1
(en)
|
2022-03-30 |
2024-10-03 |
Centessa Pharmaceuticals (Uk) Limited |
Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
CA3246312A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023194656A1
(en)
|
2022-04-08 |
2023-10-12 |
Tilt Biotherapeutics Oy |
Monoclonal pd-l1 antibodies
|
|
WO2023196964A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine learning identification, classification, and quantification of tertiary lymphoid structures
|
|
WO2023201291A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
KR20250004768A
(ko)
|
2022-04-13 |
2025-01-08 |
제넨테크, 인크. |
치료 단백질의 약학적 조성물 및 사용 방법
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
KR20250012585A
(ko)
|
2022-05-12 |
2025-01-24 |
제넨테크, 인크. |
Shp2 억제제와 pd-l1 결합 길항제를 포함하는 방법 및 조성물
|
|
US20250340641A1
(en)
|
2022-05-18 |
2025-11-06 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
CA3257280A1
(en)
|
2022-05-25 |
2023-11-30 |
Msd International Gmbh |
COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
US20250332252A1
(en)
|
2022-06-02 |
2025-10-30 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
CN119998295A
(zh)
|
2022-06-08 |
2025-05-13 |
因赛特公司 |
作为dgk抑制剂的三环三唑并化合物
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
US20250230256A1
(en)
|
2022-06-16 |
2025-07-17 |
Lamkap Bio Beta Ltd |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
US20250353842A1
(en)
|
2022-06-22 |
2025-11-20 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
EP4555093A2
(en)
|
2022-07-11 |
2025-05-21 |
Autonomous Therapeutics, Inc. |
Encrypted rna and methods of its use
|
|
WO2024015864A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
|
|
CA3261147A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
|
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN119923267A
(zh)
|
2022-07-27 |
2025-05-02 |
阿斯利康(瑞典)有限公司 |
表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
KR20250057800A
(ko)
|
2022-08-02 |
2025-04-29 |
리미널 바이오사이언시스 리미티드 |
헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
|
|
IL318576A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
Pyridoxine-substituted GPR84 antagonists and their uses
|
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
EP4568950A1
(en)
|
2022-08-08 |
2025-06-18 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
CN119768401A
(zh)
|
2022-08-11 |
2025-04-04 |
豪夫迈·罗氏有限公司 |
双环四氢硫氮杂䓬衍生物
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
CR20250043A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidrotiazepina
|
|
JP2025526727A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロチアゼピン誘導体
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
TW202417488A
(zh)
|
2022-08-23 |
2024-05-01 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
EP4606384A1
(en)
|
2022-10-19 |
2025-08-27 |
Astellas Pharma, Inc. |
Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment
|
|
WO2024086739A1
(en)
|
2022-10-20 |
2024-04-25 |
Synthekine, Inc. |
Methods and compositions of il12 muteins and il2 muteins
|
|
JP2025536252A
(ja)
|
2022-10-20 |
2025-11-05 |
アンセルム（アンスティチュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） |
癌治療のための併用療法
|
|
EP4605422A2
(en)
|
2022-10-20 |
2025-08-27 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
WO2024089417A1
(en)
|
2022-10-24 |
2024-05-02 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
|
EP4608390A1
(en)
|
2022-10-24 |
2025-09-03 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
|
KR20250093336A
(ko)
|
2022-10-25 |
2025-06-24 |
제넨테크, 인크. |
다발성 골수종에 대한 치료 및 진단 방법
|
|
KR20250089492A
(ko)
|
2022-11-07 |
2025-06-18 |
네오이뮨텍, 인코퍼레이티드 |
비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
|
|
EP4615480A1
(en)
|
2022-11-07 |
2025-09-17 |
Alector LLC |
Uses of siglec-9 ecd fusion molecules in cancer treatment
|
|
AR131099A1
(es)
|
2022-11-18 |
2025-02-19 |
Incyte Corp |
Fluoroalquenos heteroarílicos como inhibidores de dgk
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN120569191A
(zh)
|
2022-11-23 |
2025-08-29 |
乔治亚大学研究基金公司 |
用于增加免疫应答的组合物及其使用方法
|
|
KR20250113504A
(ko)
|
2022-11-29 |
2025-07-25 |
애들레이 노르티 바이오파마 컴퍼니 리미티드 |
융합 폴리펩타이드 및 그 용도
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
US20250340648A1
(en)
|
2022-12-01 |
2025-11-06 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
EP4626922A2
(en)
|
2022-12-01 |
2025-10-08 |
Innate Pharma |
Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies
|
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
EP4637807A2
(en)
|
2022-12-20 |
2025-10-29 |
Genentech Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
CN120530131A
(zh)
|
2023-01-06 |
2025-08-22 |
拉森医疗公司 |
抗il-18bp抗体
|
|
WO2024148241A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
US20240270739A1
(en)
|
2023-01-12 |
2024-08-15 |
Incyte Corporation |
Heteroaryl Fluoroalkenes As DGK Inhibitors
|
|
EP4649173A1
(en)
|
2023-01-13 |
2025-11-19 |
Akrivia Biomedics Limited |
Method of profiling diseases
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
US20240336608A1
(en)
|
2023-03-29 |
2024-10-10 |
Merck Sharp & Dohme Llc |
Il4i1 inhibitors and methods of use
|
|
WO2024208818A1
(en)
|
2023-04-04 |
2024-10-10 |
Innate Pharma |
Modular chimeric antigen receptor
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
WO2024218512A1
(en)
*
|
2023-04-19 |
2024-10-24 |
Centessa Pharmaceuticals (Uk) Limited |
Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
|
|
WO2024224323A1
(en)
|
2023-04-24 |
2024-10-31 |
King Abdullah University Of Science Of Technology |
Compositions, systems and methods for multiplex detection of target biomarkers in a sample
|
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
CN121079326A
(zh)
|
2023-05-04 |
2025-12-05 |
诺瓦森塔股份有限公司 |
抗cd161抗体及其使用方法
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
TW202509014A
(zh)
|
2023-05-10 |
2025-03-01 |
美商纜圖藥品公司 |
ＧＳＫ３α抑制劑及其使用方法
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
EP4615455A2
(en)
|
2023-06-23 |
2025-09-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025043151A2
(en)
|
2023-08-24 |
2025-02-27 |
Incyte Corporation |
Bicyclic dgk inhibitors
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250114468A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025085781A1
(en)
|
2023-10-19 |
2025-04-24 |
Genentech, Inc. |
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025096843A1
(en)
|
2023-11-03 |
2025-05-08 |
Amgen Inc. |
Bispecific molecules
|
|
WO2025106278A1
(en)
|
2023-11-17 |
2025-05-22 |
Mersana Therapeutics, Inc. |
Treatment of cancer using b7-h4-targeted antibody-drug conjugates
|
|
WO2025122545A1
(en)
|
2023-12-05 |
2025-06-12 |
Incyte Corporation |
Tricyclic triazolo compounds as dgk inhibitors
|
|
US20250186450A1
(en)
|
2023-12-06 |
2025-06-12 |
Incyte Corporation |
COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
US20250195536A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025153834A1
(en)
|
2024-01-19 |
2025-07-24 |
Institut National de la Santé et de la Recherche Médicale |
Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025188694A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Tricyclic tlr7 agonists and uses thereof
|
|
WO2025188693A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Bicyclic tlr7 agonists and uses thereof
|
|
WO2025186778A1
(en)
|
2024-03-08 |
2025-09-12 |
Janssen Biotech, Inc. |
Combinations of oncolytic viruses and immunomodulators
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|
|
WO2025191529A1
(en)
|
2024-03-14 |
2025-09-18 |
Biohaven Therapeutics Ltd. |
Next generation riluzole prodrugs
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025216894A1
(en)
|
2024-04-09 |
2025-10-16 |
Sensei Biotherapeutics, Inc. |
Bispecific anti-vista and anti-cd28 binding proteins and uses thereof
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025219595A1
(en)
|
2024-04-19 |
2025-10-23 |
Biper Therapeutics |
Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025233867A1
(en)
|
2024-05-10 |
2025-11-13 |
Adaptam Therapeutics, S.L. |
Anti-siglec-9 antibodies and uses thereof
|
|
WO2025232879A1
(en)
|
2024-05-10 |
2025-11-13 |
Cytocares (Shanghai) Inc. |
Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
WO2025254987A1
(en)
|
2024-06-03 |
2025-12-11 |
Alector Llc |
Siglec-9 ecd fusion molecule variants and methods of use thereof
|
|
WO2025252857A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
Il-15 muteins with ph-dependent binding for il-15ralpha
|
|
WO2025252855A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|
|
GB202408360D0
(en)
|
2024-06-11 |
2024-07-24 |
Cancer Research Tech Ltd |
Tumour sensitisation
|